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ABSTRACT: The utilization of Photodynamic Therapy (PDT) for the treatment of various types of cancer has gained increasing 
attention over the last decades. Despite the clinical success of approved photosensitizers (PSs), their application is limited due to poor 
water solubility, aggregation, photodegradation, and slow clearance from the body. To overcome these drawbacks, research efforts 
are devoted towards the development of metal complexes and especially Ru(II) polypyridine complexes based on their attractive 
photophysical and biological properties. Despite the recent research developments, the vast majority of complexes utilize blue or UV-
A light to obtain a PDT effect, limiting the penetration depth inside the tissue and therefore, the possibility to treat deep-seated or 
large tumors. To circumvent these drawbacks, we present the first example of the DFT guided search for efficient PDT PSs with a 
substantial spectral red shift towards the biological spectral window. Thanks to this design, we have unveiled a Ru(II) polypyridine 
complex, which causes phototoxicity in the very-low micromolar-to-nanomolar range at clinically relevant 595 nm, in monolayer 
cells as well as in 3D multicellular tumor spheroids. 
INTRODUCTION 
Photodynamic Therapy (PDT) is a non-invasive medical tech-
nique for the treatment of various types of cancer (e.g., lung, 
bladder, esophageal, and brain cancer) as well as bacterial, fun-
gal or viral infections. The effect of PDT relies on the combina-
tion of an ideally non-toxic molecule, a so-called photosensi-
tizer (PS), oxygen, and light. The PS is injected either systemi-
cally or locally. Upon light irradiation, the PS is uplifted to an 
excited singlet state from which the PS can undergo an intersys-
tem crossing process to reach an excited triplet state. This state 
can influence the biological environment either by a Type I or 
Type II pathway. A Type I mechanism is characterized by an 
electron or proton transfer from or to the PS, which leads to the 
formation of reactive oxygen species (ROS) or other highly re-
active radicals. In a Type II mechanism, the energy is trans-
ferred to triplet oxygen (3O2) to generate singlet oxygen (1O2). 
Due to their high reactivity, ROS and 1O2 can cause oxidative 
stress and damage in different cellular compartments (i.e., 
membrane, nucleus, endoplasmic reticulum, lysosome, mito-
chondria). Both of these mechanisms can happen simultane-
ously upon light irradiation even so Type II pathway is the pre-
dominant one for most approved PSs.1-6  
Photofrin is the most commonly used PS in PDT. It has been 
approved for the treatment of bladder cancer, early-stage lung 
cancer, esophageal cancer, and early non-small cell lung cancer. 
However, based on its low solubility and low absorption in the 
therapeutic window (i.e., 600-900 nm), high concentrations, as 
well as high light doses are required for an adequate tumor treat-
ment making Photofrin not an ideal PS. Additionally, it was 
shown that this PS has an exceptionally long half-life excretion 
time leading to severe photosensitivity for the patients. Since 
the majority of investigated and approved PS are based on a 
tetrapyrrolic scaffold (i.e., porphyrins, chlorins, phthalocya-
nines), these PSs are likely to have similar drawbacks which 
include 1) poor water solubility; 2) tedious synthesis and puri-
fication; 3) low cancer selectivity; 4) photobleaching effect and 
5) slow clearance from the body causing photosensitivity.
Therefore, a need for modification of existing PSs or the devel-
opment of new classes of PSs is needed.7-14
Among the new classes of PSs investigated the development of 
Ru(II) polypyridyl complexes as PDT PSs has received much 
attention due to their ideal photophysical and photochemical 
properties (i.e., high water solubility, high chemical stability 
and photostability, intense luminescence, large Stokes shifts, 
high 1O2 production).15-30 Worthy of note, the complex TLD-
1433 [Ru(dmb)2(IP-TT)]2+ (dmb=4,4′-dimethyl-2,2′-bipyri-
dine, IP-TT=2-(2′,2″:5″,2′ ′′-terthiophene)-imidazol[4,5-
f][1,10]phenanthroline) has just entered phase II clinical trial as 
a PDT PS for the treatment of non-muscle invasive bladder can-
cer in Canada.31-34 Despite these remarkable properties, the ma-
jority of Ru(II)-based PS are typically excited using blue or UV-
A light and therefore suffer from a lack of absorption in the bi-
ological spectral window (600-900 nm).35-38 Based on absorp-
tion and light scattering effects in the biological environment, 
the light penetration depth into the tissue is low at this wave-
length, which limits their application to treat deep tumors or 
large tumors.39, 40 To overcome this limitation, there is a need 
for optimization of the absorption properties of Ru(II)-based 
PSs. It has been well-established that the photophysical proper-
ties, including absorption, emission as well as excited-state life-
times of Ru(II) polypyridyl complexes depend on the ligands 
bound to the Ru center. This variable can, therefore, be tuned. 
In this context, we applied a combined experimental and theo-
retical approach to design new suitable Ru-based PDT PSs. 
Based on the already well-established biological activity of the 
complex [Ru(phen)3]2+ (phen = 1,10-phenanthroline) as a minor 
groove binder41 and [Ru(bphen)3]2+ (bphen = 4,7-diphenyl-1,10-
phenanthroline) as a mitochondria and lysosome targeting 
agent42 and their ability to be effective PDT PSs43-45, we decided 
to use [Ru(phen)2(bipy)]2+ and [Ru(bphen)2(bipy)]2+ (bipy = 
2,2’-bipyridine) derivatives as basic scaffolds. In this investiga-
tion, the electronic properties, the origin, and the magnitude of 
red shift towards the biologic spectral window are disclosed. 
The resulting complexes (1-7, Figure 1) were synthesized, char-
acterized, and biologically evaluated in-depth. Thanks to this 
combined study, a highly active Ru(II)-based PDT PS that can 
be excited up to 595 nm could be unveiled. 
RESULTS AND DISCUSSION 
Rational Design. As the basis of the design of Ru(II) polypyridine 
complexes as PDT PSs with red-shifted absorption near or in the 
biological spectral window, the [Ru(phen)2(bipy)]2+ scaffold was 
used due to its synthetic accessibility and generally high physical 
stability. To pursue this aim, systematic modification on the bipyr-
idine moiety was investigated, and these effects studied by a theo-
retical and experimental approach. 
It is well known that, in a simplified picture, the highest occu-
pied orbitals in a pseudo-octahedral Ru(II) polypyridyl complex 
are mainly consisting of the Ruthenium t2g-d-orbitals while the 
lowest occupied orbitals typically correspond  to π*-orbitals lo-
calized on the ligands.46, 47 Therefore, the lowest intense absorp-
tion band is expected to be of metal to ligand charge transfer 
(MLCT) character stemming from electronic transitions from 
the t2g manifold to the empty ligands lowest-lying orbitals and 
leading to the population of a singlet state of MLCT nature un-
der light irradiation. A simple way to red shift the MLCT ab-
sorption energy is, therefore, to decrease the HOMO-LUMO 
gap by an ad-hoc functionalization of the ligands. In particular, 
functionalization of the ligands with electron-donating and 
electron-withdrawing (EDG/EWG) groups is expected to in-
crease the occupied MOs and lower the LUMO energy, respec-
tively.  
In the case of the unsubstituted compound 1, the ligands are not 
strictly equivalent (two phen and one bipy ligand) so that the t2g 
orbitals are not expected to be strictly degenerate. Nonetheless, 
from the computed MOs energies of 1, it can be seen that the 
difference in energy between the t2g orbitals is very tiny 
(roughly 0.04 eV) and the same holds for the LUMOs of π* 
character (roughly 0.08 eV) with contributions arising both 
from the phen and the bipy ligands. As a consequence, the func-
tionalization of any of the two ligands shall induce a shift of the 
gap but is indeed expected to be easier in the case of the bipy, 
due to the reduced steric congestion around this ligand. For this 
reason, EDGs and EWGs were exclusively introduced only on 
the bipy ligand (1-5, Figure 1, optimized cartesian coordinates 
Table S1-S5). 
Figure 1. Chemical structures of the Ru(II) polypyridyl complexes 
investigated in this work. The complexes 1-7 were isolated as PF6- 
salts. 
For this purpose, the energies of the frontier molecular orbitals 
were computed (Figure 2). Indeed, functionalization with -Me 
(2) (a weakly EDG) only negligibly affects the gap (reducing
from 3.99 eV for 1 to 3.97 eV for 2). A slightly more significant 
effect is obtained by weak EWGs such as -Br (3) and -CONH2 
(4, 3.83 eV, and 3.77 eV, respectively), which induce a small
stabilization of the LUMO. These observations are in line with
the results previously obtained by some of us48 when function-
alizing with a -CHO group, a better EWG for which the com-
puted gap is indeed 3.47 eV. On the other hand, functionaliza-
tion with the vinyl dimethylamine-EDG (5) results in a substan-
tial reduction of the HOMO-LUMO gap (to 3.24 eV, roughly 
0.7 eV lower than the native compound (1) due to a sizable in-
crease of the HOMO energy. Nonetheless, it should be under-
lined that the gap is reduced here due to the presence of occu-
pied orbitals centered on the vinyl dimethylamine group in the 
gap.  Therefore, although de facto the gap is substantially re-
duced, there is no destabilization of the t2g manifold so that the 
bright MLCT transition (occurring from the t2g orbitals to the π* ligand orbitals) is expected not to be affected (that is red-
shifted).  
To capitalize on this theoretical insight, we additionally exam-
ined the functionalization with a methyl and vinyl dimethyla-
mine group on the [Ru(bphen)2(bipy)]2+ scaffold 6-7 (optimized 
cartesian coordinates Table S6-S7). Interestingly, changing the 
ligand scaffold from phen to bphen does not significantly affect 
the gap – as expected due to the small electronic effect induced 
by the presence of the four phenyl groups on the phen ligands. 
Indeed comparing compounds 2 and 6 or 5 and 7 (that are the 
analogous in the two series), a difference of only 0.1 and 
0.07 eV in the gap, respectively, can be observed.  
Figure 2. Computed frontier orbitals’ energies and HOMO-LUMO 
gaps (in eV). Occupied/virtual orbitals energies are represented as 
black/blue line. Blue background: Ru(phen)2(bipy)2+ skeleton. Pur-
ple background: Ru(bphen)2(bipy)2+ skeleton. 
Synthesis and Characterization. Based on the theoretical de-
sign, the Ru(II) polypyridine complexes 1-7 (Figure 1) were 
synthesized. To date, the synthesis of complexes 3–5 and 7 has 
not been yet reported, while complexes 149, 250, and 651 are 
known. However, in this study, slightly different experimental 
procedures than the previously described were employed to ob-
tain these compounds (for experimental protocols see support-
ing information). The identity of all complexes was confirmed 
by 1H, 13C-NMR (Scheme S1, Figures S1-S14), HRMS, and the 
purity by elemental analysis. In addition, the molecular struc-
tures of complexes 1-3 (Figure S15-17, Table S8-S9) were con-
firmed by single-crystal X-ray diffraction studies. The crystal 
structure of compound 1 has already been characterized by 
Huang and Ogawa52, with the exception that the crystal struc-
ture presented here contains one solvent molecule of acetoni-
trile per ruthenium complex. In all molecular structures, the 
Ru(II) central atom adopts a distorted octahedral geometry che-
lated by two 1,10-phenanthroline ligands and one 2,2’-bipyri-
dine ligand with Ru – N bond lengths ranging from 2.046(3) to 
2.078(3) Å, Nphen – Ru – Nphen angles from 79.48(12) to 
80.1(2)°, and Nbipy – Ru – Nbipy angles from 78.55(10) to 
78.98(13)°. It is worth to note that the substitution of the bipyr-
idine ligand by methyl groups in 2 and bromo ligands in 3 has 
no significant influence on the Ru – N bond distances. 
Photophysical properties. The absorption spectra of the com-
pounds 1-7 were measured in CH3CN (Figure S19, extinction co-
efficients Table S10) and compared with the computed spectra 
(Figure 3). Although in the simulated spectra the energy of the 
MLCT band (around 450 nm) is systematically overestimated 
while the higher energy ligand centered (LE) band (around 300 nm) 
is better reproduced, small shifts towards the spectral windows of 
interest and a rise in intensity for the lowest energy band is indeed 
observed for the compounds 5, 6 and 7. 
Figure 3. Simulated (blue) and experimental (black) spectra of 
compounds 1-7 in CH3CN (c = 7.5 µM). Computed vertical elec-
tronic transitions are depicted as vertical blue bars. Corresponding 
oscillator strength (f) is given in a.u. 
 Of note, in the case of 5 and 7, several electronic transitions are 
computed to contribute to the first -lowest energy- absorption band. 
The most intense has still an MLCT character while the one occur-
ring at lower energy (less intense than those of MLCT character) 
and responsible for the tail and red-shift of the band are predicted 
to be essentially ligand centered. These transitions are indeed of 
HOMO-LUMO type and, as discussed above, corresponding essen-
tially to a transition from the vinyl dimethylamine group to the π* 
orbitals of the ligand. This can be visualized and understood from 
the maps of the difference in density between ground (GS) and ex-
cited state (ES) for two representative transitions of compound 6 
(Figure S18a) and 7 (Figure S18b). For both complexes, the lowest 
energy transition (first electronic transition ES1) and the most in-
tense one contributing to the first band (ES 4 and ES 9 for 6 and 7, 
respectively) were analyzed. In Figure S18, density depletion/in-
crease regions upon excitation for each are represented by blue/yel-
low zones, and the barycenters of these regions - depicted as 
blue/yellow dots - can be interpreted as the position of the electron 
and hole upon excitation. It can be clearly seen that while for com-
plex 6, both transitions have a clear MLCT character though not 
necessarily involving the same ligand, in the case of 7, in agreement 
with the MO diagram, the lowest energy transition is of interligand 
type and mostly involving the vinyl dimethylamine-part. There-
fore, even if a redshift of the first absorption band is predicted and 
indeed experimentally observed, it is not necessarily expected to 
correlate with an improvement of the phototherapeutic properties 
that are indeed linked to the population of a MLCT state. 
Following this, the luminescence of the Ru(II) polypyridine com-
plexes upon excitation at 355 nm was investigated. The maxima of 
the emission signals (Figure S20) were measured and found to be 
between 600-710 nm. Interestingly, complexes 5 and 7, which 
showed the highest red shift in absorption, also demonstrated the 
strongest red shift in their emission maximum. All complexes 
demonstrated a large Stokes shift implying minimal inference be-
tween excitation and emission. The luminescence quantum yields 
were found with values between 5.0% - 1.4% (Table S10) for 1-4, 
6 and are therefore in the same range then other Ru(II) polypyridine 
complexes.53, 54 On the contrary, the luminescence of 5 and 7 were 
barely measurable - with luminescence quantum yields >0.1%. 
This is consistent with the computed vertical absorption (see be-
fore) highlighting that for these two complexes the lowest lying ex-
cited states are of LC character. This result is also in agreement 
with the exceptionally low luminescence quantum yield of (E,E’)-
4,4’-bis(N,N’-dimethylaminovinyl)-2,2’-bipyridine in dichloro-
methane (1.5%) in comparison to other substituted 2,2’-bipyri-
dines55 and of the [Ru((E,E’)-4,4’-bis(N,N’-dimethylaminovinyl)-
2,2’-bipyridine)3]2+ complex in CH3CN (>0.1%),56 which were re-
cently reported.  
The excited-state lifetimes were determined in degassed and air-
saturated CH3CN solution to investigate the influence of the pres-
ence of oxygen. The obtained values (Figure S21-S27, Table S10) 
were found to be in the nanosecond scale in a degassed (312 – 1387 
ns) and air saturated (55 – 326 ns) solution. All measured lifetimes 
were found to be in the same range as for other Ru(II) polypyridine 
complexes.53, 54 Importantly, the data shows that the presence of 
oxygen has a significant influence on the lifetime of the excited 
state for all complexes indicating that molecular oxygen can inter-
act with the triplet state of the complex. 
 The generation of singlet oxygen (1O2) was quantitatively meas-
ured upon excitation at 450 nm by two complementary methods: (i) 
direct by measurement of the phosphorescence of 1O2, (ii) indirect 
by temporal monitoring the change of absorption of a 1O2 scaven-
ger.57, 58 Complexes 1-4, 6 were found to have 1O2 quantum yields 
(Table S11) between 53-69% in CH3CN and 5-36% in an aqueous 
solution, suggesting an application as a PDT agent. These values 
are comparable with those previously reported for related com-
pounds.59, 60 In comparison, the 1O2 quantum yields of the (E,E’)-
4,4’-bis(N,N’-dimethylaminovinyl)-2,2’-bipyridine coordinated 
complexes 5 and 7 were found to be drastically lower with values 
of 22-35% in CH3CN and 7-21% in an aqueous solution. This was 
expected as these compounds show an untypical excited state be-
havior (emission, luminescence, lifetime) which is also explained 
by DFT calculations.  
Stability. The stability of a compounds is an essential parameter 
for their use as a PDT agent. As a first experiment, the stability of 
the complexes was investigated in a DMSO solution since this sol-
vent was shown to be problematic for certain drug (candidates).61-
63 For this purpose, solutions of the complexes in DMSO-d6 were 
prepared and stored in a NMR tube in the dark at room temperature. 
A 1H-NMR spectrum was measured directly after preparing the so-
lution after one, two and seven days. For complexes 1-4 and 6 (Fig-
ures S28-S31, S33), no significant change in the spectra were ob-
served, indicating that no decomposition occurred. In contrast to 
this, small changes in the spectra for compounds 5 and 7 could be 
observed. For both compounds, changes in the signals could be de-
tected after 7 days (Figures S32, S34). This indicates that these 
compounds are not stable in DMSO. To assess the compatibility of 
Table 1. IC50 values (µM) for the complexes 1-7 and Protoporphyrin IX (PpIX) in mouse colon carcinoma (CT-26), human glioblastoma 
(U87), human glioblastoma astrocytoma (U373), human cervical carcinoma (HeLa) and non-cancerous retina pigmented epithelial (RPE-
1) cell lines in the dark and upon light irradiation (480 nm, 10 min, 3.21 J cm-2).
 CT-26 U87 U373 HeLa RPE-1 
Dark  Light PI Dark  Light PI Dark  Light PI Dark  Light PI Dark  Light PI 
1 >100 >100 - >100 93.68 
± 
2.50 
>1 >100 >100 - >100 >100 - >100 >100 - 
2 >100 91.24 
± 7.54 
>1 >100 71.40 
± 
5.67 
>1 >100 >100 - >100 >100 - >100 >100 - 
3 >100 85.71 
± 9.47 
>1 >100 >100 - >100 >100 - >100 >100 - >100 >100 - 
4 >100 72.59 
± 7.44 
>1 >100 >100 - >100 >100 - >100 >100 - >100 >100 - 
5 >100 52.54 
± 6.04 




































14.3 >100 7.90 
± 
0.54 
>12.7 >100 14.85 
± 
0.81 
>6.7 >100 15.21 
± 
1.29 




the compounds under biological conditions, the stability of the 
complexes was tested in pooled human plasma. The complexes 
were incubated for 48 h in the dark with coffeine as an internal 
standard, which was previously shown to be stable under these con-
ditions64 and then analysed by HPLC (Figures S35-41). The stabil-
ity of complexes 1-4 and 6 and the previously mentioned decom-
position of compounds 5 and 7 were confirmed. Based on these 
findings, the stability of compounds 5 and 7 has been investigated 
more in detail by incubation of these complexes with shorter time 
intervals (0 h, 4 h, 12 h, 24 h, 48 h) in the dark. 5 shows first sign of 
degradation after 12 h and compound 7 after 24 h. The degradation 
of both complexes advanced in the investigated time interval, but 
still show unreacted complex even after 48 h incubation. 
Following this, the potential decomposition of the complexes upon 
light irradiation was also tested as previous studied have shown that 
the stability of metal complexes could be influenced upon light ex-
posure.65, 66 This is crucially important as some of the currently ap-
proved PDT agents are associated with a strong photobleaching ef-
fect. The complexes were exposed to a continuous LED irradiation 
at 450 nm and the absorption spectra monitored. As a positive con-
trol [Ru(bipy)3]Cl2 and as a negative control Protoporphyrin IX was 
used. The comparison of the spectra shows that complexes 1-4 and 
6 (Figure S42-46, 48) have a photobleaching effect in a similar 
range than [Ru(bipy)3]Cl2 (Figure S41). However, compounds 5 
and 7 were found to be strongly affected by light irradiation with a 
loss of about half of their absorbance after one minute (Figure S47, 
49). This effect is even stronger than that observed for Protopor-
phyrin IX (Figure S50).  
Biological Evaluation. The lipophilicity/hydrophilicity of the 
compounds was determined by measuring the distribution coeffi-
cient (logP) between an organic octanol and aqueous phosphate 
buffer saline phase (Table S12). The complexes based on a 
[Ru(phen)2(bipy)]2+ scaffold (1-5) were found with logP values be-
tween +0.2 - +0.7 and the complexes based on a 
[Ru(bphen)2(bipy)]2+ scaffold (6-7) between +1.4 - +1.7. As all 
complexes were found majorly in the organic phase, their lipo-
philicity is indicated.  
Following this, the cellular uptake of the compounds was investi-
gated. Amount of Ru metal accumulated inside the human cervical 
carcinoma (HeLa) cells upon incubation for 4 h was determined by 
inductively coupled plasma mass spectrometry (ICP-MS). As ex-
pected, the compounds 6-7 which are based on a 
[Ru(bphen)2(bipy)]2+ scaffold showed a 2.1-5.8 times higher cellu-
lar accumulation (Figure S51) in comparison to compounds 1-5, in 
agreement with their logP values.  
To determine the potential of the complexes to act as PDT 
agents, mouse colon carcinoma (CT-26), human glioblastoma 
(U87) human glioblastoma astrocytoma (U373), human cervi-
cal carcinoma (HeLa) as well as non-cancerous retina pig-
mented epithelial (RPE-1) cell lines were treated with the com-
plexes. Their cytotoxicity in the dark and upon light exposure 
was investigated using fluorometric cell viability assay (Table 
1). Ideally, a PDT PS should be non-toxic in the dark and highly 
toxic upon light exposure. Promisingly, complexes 1-5 and 7 
were found to be non-cytotoxic in the dark in all chosen cell 
lines (IC50 >100 µM), while compound 6 showed a cytotoxic 
profile in the range from 3.09 to 28.77 µM in all investigated 
cell lines. Upon irradiation at 480 nm (10 min, 3.21 J cm-2), no 
or only poor toxicity (IC50 range from >100 to 52.54 µM) was 
observed for complexes based on a [Ru(phen)2(bipy)]2+ scaffold 
(1-5). In contrast, compounds based on the 
[Ru(bphen)2(bipy)]2+ scaffold (6-7) showed a notable phototox-
icity upon light irradiation (Phototoxic index (PI)- IC50 in the 
dark/IC50 in upon irradiation, ranges from 6.5 to 42.5). This ef-
fect can be attributed to the significantly higher uptake of 6 and 
7. Overall, considering the instability of complex 7 in DMSO
and human plasma and the absence/low phototoxicity of com-
plexes 1-5, complex 6 was further studied.
Following this preliminary examination, the ability to cause a
phototoxic effect at longer wavelengths towards the biological
spectral window was further evaluated. CT-26 cell line which
was previously shown to be the strongest affected by this com-
pound was chosen for subsequent studies. Importantly, light ir-
radiation of the treated cells at 510 nm or 540 nm caused a pho-
totoxic effect (Table 2). Strikingly, even irradiation at 595 nm
generated a phototoxic effect in cells. It has to be noted that the
lack of CO2 atmosphere during irradiation also contributed to
the obtained results. Nevertheless, the calculated PI values are
reliable, as cells used as dark control were also incubated for
the same amount of time at 37 °C in non-CO2 atmosphere.
Table 2. IC50 values (µM) for 6 in mouse colon carcinoma (CT-
26) cells in the dark and upon light irradiation at 510 nm





510 nm 4.18 ± 0.56 0.20 ± 0.005 20.6 
540 nm 3.27 ± 0.64 0.34 ± 0.005 9.6 
595 nm 1.41 ± 0.003 0.06 ± 0.004 23.5 
Overall, these results make compound 6 an impressive candi-
date as a PDT agent. 
To have a deeper insight in the mechanism of action of com-
pound 6, its cellular localisation in HeLa cell line was deter-
mined by confocal microscopy experiments. After 2 h incuba-
tion (14 µM), the complex was detected in the cytoplasm (see 
Figure S52). Immunofluorescence studies with GM130 (cis-
Golgy protein), TGN46 (trans-Golgy protein), KDEL (endo-
plasmic reticulum protein retention receptor) and LAMP (lyso-
some- associated membrane glycoprotein) antibodies demon-
strated that compound 6 did not colocalize with any of them 
(Figure 4a). Correlation analysis including Pearson’s R value as 
well as Manders’ M1 and Manders’s M2 values confirmed the 
lack of colocalisation of the tested probes with complex 6 (Fig-
ure 4b). It is possible that the cytosolic localisation of our com-
plex could be explained by its binding to the cytoskeleton as 
recently reported for structurally similar complex by the group 
of MacDonnell.67 
To further study the mechanism of action of complex 6, its in-
fluence on cellular metabolism was studied. Seahorse XF in-
strument was used which allows for real time measurements of 
oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) in cells. To observe the effect of the compound 6 
on oxidative phosphorylation (ATP production in mitochondria 
through electron transport chain), the Mito Stress test was per-
formed. In this test, sequential injections of specific inhibitors 
of the electron transport chain proteins allows for determination 
of the effect that the compound has on the mitochondrial me-
tabolism of the tested cells. Briefly, the cells were treated (4 h, 
1µM) with complex 6 as well as with cisplatin and 5-ALA (5-
aminolevulinic acid) - precursor of protoporphyrin IX (PpIX), 
a known photosensitizer, as controls.68 After the incubation 
time, the cells were irradiated at 595 nm (2 h, 22.47 J cm-2, see 
Figure S53) and the Mito Stress Test was performed. Strikingly, 
the data shows that only the cells, which were treated with com-
plex 6 and irradiated, had their metabolism impaired right after 
the irradiation process. Injection of oligomycin (a specific in-
hibitor of ATP synthase) or FCCP (an uncoupling agent) did not 
affect their oxygen consumption rates. The mitochondrial mem-
brane of these cells lost the capacity to restore the proton bal-
ance. ATP production was inhibited and spare respiratory ca-
pacity (difference between OCR values of maximal respiration 
and basal respiration) was strongly reduced, contrary to the cells 
treated with complex 6 that were not irradiated (Figure 5a and 
Figure S54). 
Additional tests investigating whether the glycolysis is also af-
fected were performed. Indeed, the glycolysis process is also 
severely impaired in the cells that are treated with complex 6 
and irradiated (Figure 5b and Figure S55). It is known that the 
glycolysis process is significantly reduced during apoptosis.69 
Additionally, mitochondria are important compartment, which 
are responsible for triggering an intrinsic cell death.70 It is then 
likely that the start of apoptosis is responsible for the initial ef-
fect in the cellular metabolism observed. A similar metabolic 
Figure 4. a) Immunofluorescent images of HeLa cells treated with complex 6 (14 µM, 30 min). DNA visualised by NucBlue staining, 
immunofluorescence for GM130, TGN46, KDEL and LAMP proteins shown in green, complex 6 shown in red. Scale bar, 20 µm. b) 
Person’s R, Manders’ M1 and Manders’ M2 colocalisation values obtained for complex 6 and fluorescent probes. 
response could not be noticed for the cisplatin. This phenome-
non could be explained by the short incubation time (only 4 h) 
and the very low concentration tested (1 µM) that is not suffi-
cient to trigger apoptosis by this drug in CT-26 cell line. Over-
all, compound 6 has an immediate effect on irradiated cells but 
not in the ones kept in the dark, resulting in disturbed mito-
chondrial respiration and glycolysis process.  
Figure 5. a) Mito Stress Test profile in CT-26 cells after 4 h treat-
ment and 2 h irradiation at 595 nm; oxygen consumption rate 
changes after treatment with specific electron transport chain inhib-
itors, namely oligomycin (inhibitor of ATP synthase (complex V)), 
FCCP (uncoupling agent), antimycin-A (complex III inhibitor) and 
rotenone (complex I inhibitor). b) Glycolysis Stress Test profile in 
CT-26 cells after 4 h treatment and 2 h irradiation at 595 nm; ex-
tracellular acidification rate that corresponds to the glycolysis pro-
cess changes after treatment with glucose (basal level of glycolysis 
in cells), oligomycin (inhibitor of ATP synthase (complex V)- mi-
tochondria inhibition), 2-deoxyglucose (analog of glucose that in-
hibits glycolytic pathway). 
After evaluation of the (photo-)cytotoxicity on 2D monolayer 
cells, the effect of complex 6 on multicellular tumor spheroids 
(MCTS) was investigated. This is of special interest as many 
anticancer drug candidates have failed the translation from 
monolayer cells to an in vivo model due to compromised drug 
delivery. MCTS are small spherical cell aggregates that mimic 
cell tumors. They can simulate the gradient of nutrients availa-
bility from upper cell layers, that are highly exposed, to lower 
layers and are able to model the potential penetration of a drug 
inside a 3D struture.71, 72 Therefore, compound 6 was incubated 
for 24 h in HeLa MCTS and its cytotoxic effect determined by 
measurement of the ATP concentration. Importantly, upon irra-
diation at 595 nm (2 h, 22.47 J cm-2), compound 6 showed a 
phototoxic effect (IC50,dark = 29.42 ± 4.60 μM, IC50,595nm = 20.07 
± 4.15 μM, PI595nm = 1.5), indicating that the compound is able 
to exert its action inside the 3D MCTS and act as a PDT agent. 
CONCLUSION 
In summary, we have combined the theoretical understanding pro-
vided by DFT calculations with the photophysical and biological 
experimental evaluation of Ru(II) polypyridine complexes as PSs 
for PDT. Thanks to this rational design, ruthenium complexes with 
a strong red shift in their absorption profile could be successfully 
prepared. While the (E,E’)-4,4’-bis(N,N’-dimethylaminovinyl)-
2,2’-bipyridine coordinated complexes showed the desired red 
shift, they were however found to have poor photophysical proper-
ties (luminescence, 1O2 production) and poor stability. In contrast, 
the [Ru(bphen)2(bmb)]2+ complex was found to have an absorption 
tail towards the biological spectral window. While being stable in 
human plasma as well as upon light irradiation, it was found to lo-
calize in the cytoplasm of HeLa cells. Upon irradiation at clinically 
relevant 595 nm it led to the disturbance of mitochondrial respira-
tion and glycolysis process in 2D monolayer cells as well as 3D 
MCTS. We strongly believe that the rational design approach to 
unveil novel (metal-based) PDT PSs have a great potential in the 
development of PSs for long-wavelength PDT. We are planning to 
investigate the in vivo efficiency of compound 6 in the future. 
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All calculations were performed using the Gaussian 091 software package. All calculations were 
performed using the Los Alamos LANL22 effective core potential and the corresponding triple-
zeta basis set for the Ruthenium atom, with all other atoms treated with the Pople double-zeta 
basis set with a single set of polarisation and diffuse functions on non-hydrogen atoms (6-
31+G(d)3, 4. Solvent effects (here acetonitrile) were included using an implicit model (i.e. the 
Polarizable Continuum Model – PCM5. All geometry optimisations were performed using 
density functional theory (DFT) with the global hybrid B3LYP6 exchange-correlation 
functional and all minima on the potential energy surface were verified via a calculation of 
vibrational frequencies, ensuring no imaginary frequencies were present. Excited states of all 
compounds (as shown in Scheme 1) were probed using time dependent density functional 
theory  (TD-DFT7) combined with the same exchange correlation functional and basis set. All 
transitions (singlet-singlet) were calculated vertically with respect to the singlet ground state. 
Absorption spectra were simulated by convolution with Gaussian functions with a full width at 
half maximum (FWHM) of 0.3 eV. In order to characterize the nature of the lowest energy 
states of interest (see discussion), relaxed excited state density was also computed together with 
the corresponding associated charge transfer distance (DCT)
8. In brief the DCT index provides a 
measure of the spatial extent of a given transition and yields a coherent representation of the 
charge rearrangements occurring upon generation of the exciton based on the ground and 
excited states density distributions. Details on how to calculate the DCT index are reported in 
refs.8, 9
Materials 
All chemicals were obtained from commercial sources and were used without further 
purification. Solvents were dried over molecular sieves if necessary. The Ru(II) complexes 
dichlorobis(1,10-phenanthroline)ruthenium(II) [RuCl2(phen)2] and dichlorobis(4,7-Diphenyl-
1,10-phenanthroline)ruthenium(II) [RuCl2(bphen)2] were synthesised as previously published 
using the respective ligands.10 The substituted bipyridine ligands 2,2’-bipyridine-4,4’-
dicarbonitrile11 and (E,E’)-4,4’-bis(N,N-dimethylaminovinyl)-2,2’-bipyridine12 were 
synthesised as previously reported.
2 
Instrumentation and methods 
1H and 13C NMR spectra were recorded on a Bruker 400 MHz or Bruker 500 MHz NMR 
spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) referenced to 
tetramethylsilane (δ 0.00) ppm using the residual proton solvent peaks as internal standards. 
Coupling constants (J) are reported in Hertz (Hz) and the multiplicity is abbreviated as follows: 
s (singlet), d (doublet), dd (doublet of doublet), t (triplet), m (multiplet). ESI mass spectra were 
recorded on a Bruker ESQUIRE-LC quadrupole ion trap spectrometer. Elemental 
microanalyses were performed on a LecoCHNS-932 elemental analyser or a Thermo Flash 
2000 elemental analyser. Inductively coupled plasma mass spectrometry (ICP-MS) 
experiments were carried out on HR-ICP-MS Element II (Thermo Scientific) apparatus. 
Synthesis 
Proton and carbon NMR spectra can be found in the supplemental information (Figures S1-14). 
(1) [Ru(bpy)(phen)2](PF6)2
(2,2’-Bipyridine)bis(1,10-phenanthroline)ruthenium(II)hexafluorophosphate  
The synthesis of [Ru(bipy)(phen)2](PF6)2 is already published13 but in this study another 
synthetic route was employed. RuCl2(phen)2 (150 mg, 0.28 mmol, 1.0 equiv.) and 2,2′-
bipyridine (48 mg, 0.31 mmol, 1.1 equiv.) were dissolved in 8 mL MeOH and refluxed for 18 h 
under N2 atmosphere. After this time, the volume of the brown mixture was reduced to 1/4. A 
saturated, aq. NH4PF6 solution was added and the resulting precipitate was collected by vacuum 
filtration and washed with H2O (50 mL) and Et2O (50 mL). The product was dried in high 
vacuum. Yield: 51%. 1H NMR (500 MHz, CD3CN) δ = 8.65 (dd, 2H, J = 8.3, 1.3 Hz), 8.55 (dd, 
2H, J = 8.2, 1.3 Hz), 8.52 (d, 2H, J = 8.3 Hz), 8.26 (d, 2H, J = 8.9 Hz), 8.23 (d, 2H, J = 8.9 Hz), 
8.20 (d, 2H, J = 5.2 Hz), 8.03 (td, 2H, J = 8.1, 1.4 Hz), 7.88 (dd, 2H, J = 5.3, 1.2 Hz), 7.79 (dd, 
2H, J = 8.3, 5.2 Hz), 7.67 (d, 2H, J = 5.6 Hz), 7.56 (dd, 2H, J = 8.2, 5.3 Hz), 7.27 (ddd, 2H, J 
= 7.3, 5.6, 1.3 Hz); 13C NMR (125 MHz, CD3CN) δ = 158.3, 153.8, 153.6, 153.2, 148.8, 148.6, 
138.7, 137.8, 137.7, 132.0, 132.0, 129.0, 129.0, 128.3, 127.0, 126.8, 125.1; HRMS (ESI⁺ m/z): 
Calcd. for [C34H24F12N6P2Ru-2PF6]2+: 309.05478, Found: 309.05475, Calcd. for 
[C34H24F12N6P2Ru-PF6]+: 763.07423, Found: 763.07434; Anal. Calcd. for C34H24F12N6P2Ru: 







The synthesis of [Ru(dmb)(phen)2](PF6)2 is already published14 but in this study another 
synthetic route was employed. RuCl2(phen)2 (150 mg, 0.28 mmol, 1.0 equiv.) and 4,4’-
dimethyl-2,2’-bipyridine (57 mg, 0.31 mmol, 1.1 equiv.) were dissolved in a 1:1 mixture of 
H2O/EtOH (7 mL) and were refluxed for 18 h under N2 atmosphere. The solvent was evaporated 
to one third of the volume and a saturated, aq. NH4PF6 solution was added. The resulting 
precipitate was collected by vacuum filtration and washed with H2O (50 mL) and Et2O (50 mL). 
The product was dried in high vacuum. Yield: 97%. 1H NMR (400 MHz, CD3CN) δ = 8.64 (dd, 
2H, J = 8.3, 1.3 Hz), 8.53 (dd, 2H, J = 8.3, 1.3 Hz), 8.37 (s, 2H), 8.25 (d, 2H, J = 8.9 Hz), 8.22 
(d, 2H, J = 8.9 Hz) 8.20 (dd, J = 5.3, 1.3 Hz), 7.88 (dd, 2H, J = 5.3, 1.3 Hz), 7.79 (dd, 2H, J = 
8.3, 5.3 Hz), 7.54 (dd, 2H, J = 8.2, 5.3 Hz), 7.47 (d, 2H, J = 5.8 Hz), 7.10 (dd, 2H, J = 5.8, 1.2 
Hz), 2.51 (s, 6H); 13C NMR (100 MHz, CD3CN) δ = 157.8, 153.6, 153.6, 152.2, 151.3, 148.9, 
148.7, 137.6, 137.5, 131.9, 131.9, 129.0, 129.0, 129.0, 126.9, 126.8, 125.8, 21.2; HRMS (ESI⁺ 
m/z): Calcd. for [C36H28F12N6P2Ru-2PF6]2+: 323.07040, Found: 323.07040; Anal. Calcd. for 




RuCl2(phen)2 (150 mg, 0.28 mmol, 1.0 equiv.) and 4,4’-Dibromo-2,2’-bipyridine (105 mg, 
0.34 mmol, 1.2 equiv.) were dissolved in a 1:1 mixture of H2O/EtOH (40 mL) and were refluxed 
for 18 h under N2 atmosphere. The solvent was evaporated and the residue redissolved in 5 mL 
of H2O. A saturated, aq. NH4PF6 solution was added and the resulting precipitate was collected 
by vacuum filtration. The solid was washed with H2O (50 mL) and Et2O (50 mL). The product 
was isolated by column chromatography on silica gel with an CH3CN/aq. KNO3 (0.4 M) 
solution (10:1). The fractions containing the product were united and the solvent was removed. 
The residue was dissolved in CH3CN and undissolved KNO3 was removed by filtration. The 
solvent was removed and the product was dissolved in H2O (50 mL). Upon addition of NH4PF6 
the product precipitated as a PF6 salt. The solid was obtained by filtration and was washed with 
H2O (50 mL) and Et2O (50 mL). The product was dried in high vacuum. Yield: 78%. 1H NMR 
(500 MHz, CD3CN) δ = 8.76 (2H, d, J = 2.0 Hz), 8.68 (2H, dd, J = 8.3, 1.3 Hz), 8.55 (2H, dd, 




Hz), 7.84 (2H, dd, J = 5.3, 1.3 Hz), 7.81 (2H, dd, J = 8.3 , 5.2 Hz), 7.55 (2H, dd, J = 8.3, 5.3 
Hz), 7.50 (2H, d, J = 6.1 Hz), 7.47 (2H, dd, J = 6.1, 2.0 Hz). 13C NMR (125 MHz, CD3CN) δ 
= 158.3, 154.0, 153.9, 153.6, 148.7, 148.4, 138.0, 137.9, 134.7, 132.0, 132.0, 131.7, 129.1, 
129.0, 129.0, 127.0, 126.9. HR-MS (ESI⁺ m/z): Calcd. [M-2PF₆]²⁺: 386. 96526; found: 386. 
96576. Anal. (%): Calcd. for (C34H22Br2F12N6P2Ru): C 38.33, H 2.08, N 7.89; found. C 38.62, 




RuCl2(phen)2 (150 mg, 0.28 mmol, 1.0 equiv.) and 2,2’-Bipyridine-4,4’-dicarbonitrile (64 mg, 
0.31 mmol, 1.1 equiv.) were dissolved in a 1:1 mixture of H2O/EtOH (30 mL) and were refluxed 
for 18 h under N2 atmosphere. The solvent was evaporated and the residue redissolved in 5 mL 
of H2O. A saturated, aq. NH4PF6 solution was added and the resulting precipitate was collected 
by vacuum filtration. The solid was washed with H2O (50 mL) and Et2O (50 mL). The product 
was purified by column chromatography on silica gel with an CH3CN /aq. KNO3 (0.4 M) 
solution (10:1). The fractions containing the product were united and the solvent was removed. 
The residue was dissolved in CH3CN and undissolved KNO3 was removed by filtration. The 
solvent was removed again and the product was dissolved in H2O (50 mL). Upon addition of 
NH4PF6 the product precipitated as a PF6 salt. The solid was obtained by filtration and was 
washed with H2O (50 mL) and Et2O (50 mL). The product was dried in high vacuum. Yield: 
16%. 1H NMR (400 MHz, CD3CN) δ = 8.97 (2H, s), 8.67 (2H, d, J = 8.3 Hz), 8.58 (2H, d, J = 
8.3 Hz), 8.30-8.22 (4H, m), 8.18 (2H, d, J = 5.2 Hz), 7.87-7.84 (4H, m), 7.79 (2H, dd, J = 8.3, 
5.2 Hz), 7.61-.7.57 (4H, m), 7.25 (2H, s), 6.48 (2H, s). 13C NMR (100 MHz, CD3CN) δ = 165.7, 
158.8, 154.0, 153.9, 153.5, 148.6, 148.3, 143.0, 138.2, 138.0, 132.1, 132.0, 129.1, 129.0, 127.0, 
127.0, 126.0, 123.1. HR-MS (ESI⁺ m/z): Calcd. [M-2PF₆]²⁺ : 352.06056; found: 352.06063. 








[Ru(dmb)(phen)2](PF6)2 (2) (100 mg, 0.11 mmol, 1.0 equiv.) was dissolved in dry DMF 
(1.5 mL) and tert-butoxy bis(dimethylamino)methane (0.2 mL, 0.97 mmol, 8.8 equiv.) was 
added. The mixture was heated at 140 °C for 16 h under N2 atmosphere. The solution was 
cooled down and an aq. solution of NH4PF6 was added. The resulting precipitate was collected 
by vacuum filtration and the solid was washed with H2O (50 mL) and Et2O (50 mL). The 
product was isolated via fractionated precipitation from CH3CN by adding dropwise Et2O and 
afterwards dried in high vacuum. Yield: 41%. 1H NMR (400 MHz, CD3CN) δ = 8.61 (2H, dd, 
J = 8.3, 1.3 Hz), 8.48 (2H, dd, J = 8.3, 1.3 Hz), 8.38 (2H, dd, J = 5.3, 1.3 Hz), 8.24 (2H, d, J 
= 8.9 Hz), 8.19 (2H, J = 9.0 Hz), 8.08 (2H, d, J = 2.2 Hz), 7.87 (2H, dd, J = 5.3, 1.3 Hz), 7.82 
(2H, dd, J = 8.2 Hz, 5.3 Hz), 7.52 (2H, dd, J = 8.2 Hz, 5.3 Hz), 7.51 (2H, d, J = 13.3 Hz), 6.99 
(2H, d, J = 6.2 Hz), 6.77 (2H, dd, J = 6.2, 2.1 Hz), 5.08 (2H, d, J = 13.4 Hz), 2.94 (12H, s). 
13C NMR (100 MHz, CD3CN) δ = 157.6, 153.5, 153.5, 151.6, 150.6, 149.2, 149.1, 147.8, 137.0, 
137.0, 131.9, 131.9, 129.0, 129.0, 126.9, 126.7, 120.3, 117.1, 92.9, 40.1. HR-MS (ESI⁺ m/z): 
Calcd. [M-2PF₆]²⁺: 378.11260; found: 378.11289. Anal. (%): Calcd. for (C42H38F12N8P2Ru): C 
48.24, H 3.66, N 10.71; found: C 47.97, H 3.59, N 10.76. 
(6) [Ru(dmb)(bphen)2](PF6)2 < 
(4,4′-Dimethyl-2,2′-bipyridine)bis(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) 
hexafluorophosphate  
The synthesis of [Ru(dmb)(bphen)2](PF6)2 is already published15 but in this study another 
synthetic route was employed. RuCl2(bphen)2 (200 mg, 0.24 mmol, 1.0 equiv.) and 4,4’-
Dimethyl-2,2’-bipyridine (53 mg, 0.29 mmol, 1.2 equiv.) were dissolved in a 1:1 mixture of 
H2O/EtOH (10 mL) and were refluxed for 18 h under N2 atmosphere. The solvent was 
evaporated and the residue redissolved in 10 mL of H2O. A saturated, aq. NH4PF6 solution was 
added and the suspension was sonicated. 60 mL of H2O were added and the resulting precipitate 
was collected by vacuum filtration. The solid was washed with H2O (50 mL) and Et2O (50 mL). 
The product was dried in high vacuum. Yield: 93%. 1H NMR (400 MHz, CD3CN) δ = 8.44 
(2H, s), 8.29 (2H, d, J = 5.5 Hz), 8.22-8.16 (m, 4H), 8.10 (2H, d, J = 5.5 Hz), 7.75 (2H, d, J = 
5.5 Hz), 7.72 – 7.53 (24H, m), 7.21 (2H, d, J = 5.8, J = 1.7 Hz), 2.56 (6H, s). 13C NMR (125 
MHz, CD3CN) δ = 157.7, 153.1, 152.9, 152.2, 151.4, 149.9, 149.8, 149.5, 149.4, 136.7, 136.7, 
130.8, 130.7, 130.7, 130.6, 130.6, 130.1, 130.1, 130.1, 129.9, 129.9, 129.1, 127.1, 127.0, 127.0, 









[Ru(dmb)(bphen)2](PF6)2 (7) (150 mg, 0.12 mmol, 1.0 equiv.) was dissolved in dry DMF 
(1.5 mL) and tert-butoxy bis(dimethylamino)methane (0.3 mL, 1.45 mmol, 12.1 equiv.) was 
added. The mixture was heated at 140 °C for 18 h under N2 atmosphere. After this time, more 
tert-butoxy bis(dimethylamino)methane (0.4 mL, 1.94 mmol, 16.2 equiv.) was added the 
mixture was heated at 145 °C for 72 h under N2 atmosphere. The solution was cooled down and 
an aq. solution of NH4PF6 was added. The resulting precipitate was collected by vacuum 
filtration and the solid was washed with H2O (50 mL) and Et2O (50 mL). The product was 
isolated via fractionated precipitation from CH3CN by adding dropwise Et2O and afterwards 
dried in high vacuum. Yield: 67%. 1H NMR (500 MHz, CD3CN) δ = 8.48 (2H, d, J = 5.5 Hz), 
8.20 (2H, d, J = 9.4 Hz), 8.16 8.20 (2H, d, J = 9.5 Hz), 8.13 (2H, d, J = 2.11 Hz), 8.09 (2H, d, 
J = 5.5 Hz), 7.80 (2H, d, J = 5.5 Hz), 7.69 – 7.52 (22H, m), 7.21 (2H, d, J = 6.2 Hz), 6.87 (2H, 
dd, J = 6.3, 2.0 Hz), 5.14 (2H, d, J = 13.4 Hz), 2.96 (12H, s). 13C NMR (125 MHz, CD3CN) δ 
= 157.4, 152.9, 152.7, 151.5, 150.6, 149.7, 149.6, 149.2, 149.2, 149.2, 149.2, 149.2, 147.7, 
136.9, 136.8, 130.8, 130.7, 130.7, 130.5, 130.5, 130.1,130.0, 130.0, 129.7, 129.7, 127.1, 126.9, 
126.8, 126.8, 120.2, 117.0, 92.7, 40.7. HR-MS (ESI⁺ m/z): Calcd. [M‑2PF₆]²⁺: 530.17520; 
found: 530.17584. Anal. (%):  Calcd. for (C66H54F12N8P2Ru)·(H2O)0.5: C 58.32, H 4.08, N 8.24; 
found: C 58.17, H 3.83, N 8.66.
X-ray crystallography
Single crystal X-ray diffraction data were collected at 183(1) K on a Rigaku OD SuperNova
(Atlas CCD detector) diffractometer for 1 and 2 and on a Rigaku OD Xcalibur (Ruby CCD
detector) diffractometer for 3 equipped with Oxford liquid-nitrogen Cryostream coolers. A
single wavelength X-ray source from a micro-focus sealed X-ray tube was used with the Cu Kα
radiation (λ = 1.54184 Å) for 1 and 2 and with the Mo Kα radiation (λ = 0.71073 Å) for 3. The
selected single crystals were mounted using polybutene oil on a flexible loop fixed on a
goniometer head and transferred to the diffractometer. Pre-experiments, data collections, data
reductions and analytical absorption corrections16 were performed with the program suite




structure solution program and refined with the SHELXL2018/1 program package20 by full-
matrix least-squares minimization on F2. The crystal data collections and structure refinement 
parameters are gathered in Tables S1 and S2. CCDC 1969709 (for 1),  1969708 (for 2), and 
1969710 (for 3) contain the supplementary crystallographic data for these compounds, and can 
be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
In the crystal structure of 1, solvent molecules of acetonitrile cocrystallized with the main 
species, one molecule could easily be introduced in the model and freely refined but a second 
one was observed badly disordered in the asymmetric unit. Consequently, the PLATON 
SQUEEZE tool21 was used to take the solvent contribution into account to the calculated 
structure factors: a total number of 92 electrons were found in the P1 unit cell that were 
considered as 4 solvent molecules of acetonitrile (one per asymmetric unit). In the crystal 
structure of 2, the PF6 counterions occupy three different positions in the asymmetric unit: one 
general position and two special positions (centers of inversions). The F atoms of one PF6 are 
disordered over two sets of positions. Solvent molecules of tetrahydropyran cocrystallized with 
the main species. They occupy two general positions and are disordered over two sets of 
positions. Solvent molecules of water are also present in the crystal. The non H atoms of the 
solvent molecules were isotropically refined. In the crystal structure of 3, the PF6 counterions 
occupy two different positions in the asymmetric unit and in both independent molecules the F 
atoms are disordered over two sets of positions. There are also two solvent molecules of 
acetonitrile in the asymmetric unit, one is fully disordered over two sets of positions. 
Spectroscopic measurements 
The absorption of the samples in cuvettes has been measured with a Lambda 800 UV/VIS 
Spectrometer (PerkinElmer Instruments) and in 96 well plates with a SpectraMax M2 
Spectrometer (Molecular Devices) or with a Varian Cary 8454” UV/Visible spectrophotometer 
and quartz cuvettes (width 1 cm) at c = 7.5 µM The emission was measured by irradiation of 
the sample in fluorescence quartz cuvettes (width 1 cm) using a NT342B Nd-YAG pumped 
optical parametric oscillator (Ekspla) at 355 nm. Luminescence was focused and collected at 
right angle to the excitation pathway and directed to a Princeton Instruments Acton SP-2300i 






For the determination of the lifetimes, the samples were prepared in an air saturated and in a 
degassed CH3CN solution with an absorbance of 0.1 at 355 nm. This solution was irradiated in 
fluorescence quartz cuvettes (width 1 cm) using a NT342B Nd-YAG pumped optical 
parametric oscillator (Ekspla) at 355 nm. The emission signal was focused and collected at right 
angle to the excitation pathway and directed to a Princeton Instruments Acton SP-2300i 
monochromator. As a detector a R928 photomultiplier tube (Hamamatsu) was used. 
Luminescence quantum yield measurements 
For the determination of the luminescence quantum yield, the samples were prepared in an 
CH3CN solution with an absorbance of 0.1 at 355 nm. This solution was irradiated in 
fluorescence quartz cuvettes (width 1 cm) using a NT342B OPO pulse laser Nd-YAG pumped 
optical parametric oscillator (Ekspla) at 355 nm. The emission signal was focused and collected 
at right angle to the excitation pathway and directed to a Princeton Instruments Acton SP-2300i 
monochromator. As detector a XPI-Max 4 CCD camera (Princeton Instruments) was used. The 
luminescence quantum yields were determined by comparison with the reference 






F =  1 −  10  
Φem = luminescence quantum yield, F = fraction of light absorbed, I = integrated emission 
intensities, n = refractive index, A = absorbance of the sample at irradiation wavelength 
Singlet oxygen measurements  
- direct evaluation
The samples were prepared in an air saturated CH3CN or D2O solution with an absorbance of
0.2 at 450 nm. This solution was irradiated in fluorescence quartz cuvettes (width 1 cm) using
a mounted M450LP1 LED (Thorlabs) whose irradiation, centred at 450 nm, has been focused
with aspheric condenser lenses. The intensity of the irradiation has been varied using a T-Cube
LED Driver (Thorlabs) and measured with an optical power and energy meter. The emission
signal was focused and collected at right angle to the excitation pathway and directed to a




front of the monochromator entrance slit to cut off light at wavelengths shorter than 850 nm. 
The slits for detection were fully open. As a detector an EO-817L IR-sensitive liquid nitrogen 
cooled germanium diode detector (North Coast Scientific Corp.) has been used. The singlet 
oxygen phosphorescence at 1270 nm was measured by recording spectra from 1100 to 1400 nm. 
For the data analysis, the singlet oxygen luminescence peaks at different irradiation intensities 
were integrated. The resulting areas were plotted against the percentage of the irradiation 
intensity and the slope of the linear regression calculated. The absorbance of the sample was 
corrected with an absorbance correction factor. As reference for the measurement in an CH3CN 
solution phenalenone (Φphenaleone = 0.95)23 and for the measurement in a D2O solution 
[Ru(bipy)3]Cl2 (ΦRu(bipy)₃Cl₂ = 0.22)24 was used and the singlet oxygen quantum yields were 





I = I × (1 − 10 ) 
Φ = singlet oxygen quantum yield, S = slope of the linear regression of the plot of the areas of 
the singlet oxygen luminescence peaks against the irradiation intensity, I = absorbance 
correction factor, I0 = light intensity of the irradiation source, A = absorbance of the sample at 
irradiation wavelength. 
- indirect evaluation
For the measurement in CH3CN: The samples were prepared in an air-saturated CH3CN
solution containing the complex with an absorbance of 0.1 at the irradiation wavelength, N,N-
dimethyl-4-nitrosoaniline aniline (RNO, 24 µM) and imidazole (12 mM). For the measurement
in PBS buffer: The samples were prepared in an air-saturated PBS solution containing the
complex with an absorbance of 0.1 at the irradiation wavelength, N,N-dimethyl-4-nitrosoaniline
aniline (RNO, 20 µM) and histidine (10 mM). The samples were irradiated on 96 well plates
with an Atlas Photonics LUMOS BIO irradiator for different times. The absorbance of the
samples was measured during these time intervals with a SpectraMax M2 Microplate Reader
(Molecular Devices). The difference in absorbance (A₀-A) at 420 nm for the CH3CN solution
or at 440 nm a PBS buffer solution was calculated and plotted against the irradiation times.
From the plot the slope of the linear regression was calculated as well as the absorbance
correction factor determined. The singlet oxygen quantum yields were calculated using the




Stability in DMSO 
The stability of the complexes in DMSO was determined by 1H-NMR spectroscopy. The 
complexes were dissolved in 0.7 mL DMSO-d6 [2 mg/mL] and the filled tube stored at room 
temperature in the dark. A spectrum was measured directly after preparing the solutions and 
after 1, 2 and 7 days. 
Stability in human plasma 
The stability of the complexes was evaluated with Caffeine as an internal standard, which has 
already shown to be suitable for these experiments.25 The pooled human plasma was obtained 
from Biowest and caffeine from TCI Chemicals. Stock Solutions of the compounds (40 µM) 
and caffeine (40 or 20 µM) were prepared in DMSO. One aliquot of the solutions was added to 
975 µL of human plasma to a total volume of 1000 µL. Final concentrations of the compounds 
of 0.5 µM and caffeine of 0.5 or 0.25 µM were achieved. The resulting solution was incubated 
for 4 h, 12 h, 24 h and 48 h at 37 °C with continuous gentle shaking (ca. 300 rpm). The reaction 
was stopped after the incubation time by addition of 2 mL of methanol. The mixture was 
centrifuged for 45 min at 650 g at 4 °C. The methanolic solution was filtered through a 0.2 µm 
membrane filter. The solvent was evaporated under reduced pressure and the residue was 
dissolved in 1:1 (v/v) CH3CN/ H2O 0.1 % TFA solution. The solution was filtered through a 
0.2 µm membrane filter and analysed using a HPLC System. For analytic HPLC the following 
system has been used: 2 x Agilent G1361 1260 Prep Pump system with Agilent G7115A 1260 
DAD WR Detector equipped with an Agilent Pursuit XRs 5C18 (100 Å, C18 5 µm 
250 × 4.6 mm) Column and an Agilent G1364B 1260-FC fraction collector. The flow rate was 
1 mL/min and the chromatogram was detected at 250 nm. In this study, the chromatograms 
were recorded using two different methods. Method M1: The solvents (HPLC grade) were 
millipore water (0.1 % TFA, solvent A) and acetonitrile (solvent B). 0-3 minutes: isocratic 95 % 
A (5 % B); 3-17 minutes: linear gradient from 95 % A (5 % B) to 0 % A (100 % B); 17-23 
minutes: isocratic 0 % A (100% B). Method M2: The solvents (HPLC grade) were millipore 
water (0.1 % TFA, solvent A) and acetonitrile (0.1 % TFA, solvent B). 0-3 minutes: isocratic 
95 % A (5 % B); 3-17 minutes: linear gradient from 95 % A (5 % B) to 0 % A (100 % B); 17-





The samples were prepared in an air saturated CH3CN solution with an absorbance of about 0.5 
at 450 nm. To measure the photostability, the samples were irradiated at 450 nm in 96 well 
plates with an Atlas Photonics LUMOS BIO irradiator during time intervals from 0-10 min. 
The absorbance spectrum from 350-700 nm was recorded with a SpectraMax M2 Microplate 
Reader (Molecular Devices) after each time interval and compared. As a positive control 
[Ru(bipy)3]Cl2 and as a negative control Protoporphyrin IX has been used. 
Distribution coefficient  
The lipophilicity of a complex was determined by measuring its distribution coefficient 
between the PBS and Octanol phase by using the “shake-flask” method. For this technique, the 
used phases were previously saturated in each other. The complex was dissolved in the phase 
(A) with its major presence with an absorbance of about 0.5 at 450 nm. This solution was then 
mixed with an equal volume of the other phase (B) at 80 rpm for 8 h with an Invitrogen sample 
mixer and then equilibrated overnight. The phase A was then carefully separated from phase B. 
The amount of the complex before and after the sample mixing was determined by UV/Vis 
spectroscopy at 450 nm using a SpectraMax M2 Microplate Reader (Molecular Devices). The 
evaluation of the complexes was repeated three times and the ratio between the organic and 
aqueous phase calculated.
Cell culture 
HeLa and CT-26 cell lines were cultured in DMEM media (Gibco, Life Technologies, USA) 
supplemented with 10 % of fetal calf serum (Gibco). U87 and U373 cell lines were cultured in 
MEM media with addition of 1 % of MEM NEAA (non-essential amino acids) (Gibco) and 
10 % of fetal calf serum. RPE-1 cells were cultured in DMEM/F-12 (Gibco) supplemented with 
10 % of fetal calf serum. All cell lines were complemented with 100 U/mL penicillin-
streptomycin mixture (Gibco) and maintained in humidified atmosphere at 37 °C and 5 % of 
CO2. 
Cellular uptake  
The cellular uptake of the complex was investigated by the determination of the Ru content 
inside the cells. The complex with a final concentration of 25 μM (2% DMSO, v%) was 
incubated for 4 h at 37 °C on a cell culture dish with a density of ca. 5 . 106 cells in 10 mL of 




cells were trypsinised, harvested, centrifuged and resuspended. The number of cells on each 
dish was accurately counted. Each sample was the digested using a 60% HNO3 solution for 
three days. The acid was removed and the residue dissolved in 2% HCl in water. The Ru content 
was determined using an ICP-MS apparatus and comparing the results with the Ru references. 
The Ru content was then associated with the number of cells. 
(Photo-)cytotoxicity 
Dark and light cytotoxicity of the the Ru(II) complexes was assesed by fluorometric cell 
viability assay using resazurin (ACROS Organics). For dark and light cytotoxicity, cells were 
seeded in triplicates in 96 well plates at a density of 4000 cells per well in 100 µL, 24 h prior to 
treatment. The medium was then replaced with increasing concentration of the tested complexes 
and cells were incubated for 4 h. Medium was then replaced for fresh complete medium. Cells 
used for light cytotoxicity experiment were exposed to: 480 nm light for 10 min, 510 nm for 
40 min, 540 for 60 min or 595 nm for 120 min in a 96-well plate using a LUMOS-BIO 
photoreactor (Atlas Photonics). Each well was individually illuminated with a LED at constant 
current. After irradiation cells were kept for another 44 h in the incubator and the medium was 
replaced by fresh complete medium containing resazurin (0.2 mg mL-1 final concentration). 
After 4 h incubation at 37 °C, the fluorescence signal of the resorufin product was read by 
SpectraMax M5 mictroplate reader (ex: 540 nm em: 590 nm). IC50 values were calculated using 
GraphPad Prism software. 
Cellular localisation  
HeLa cells were grown on the 12 mm Menzel–Gläser coverslips in 2 ml of complete medium 
at a density of 1.3 x 105 cells per ml. Cells were then treated with the compounds (IC50 
concentration in the dark) for 2 h, with NucBlue (2 drops per 1 ml of media) for the last 25 min 
and with 100 nm Mitotracker Green FM for the last 15 min. HeLa cells were then fixed with 
paraformaldehyde solution in PBS (4%) and mounted on glass slides using Prolong Glass 
Antifade Mountant. Leica SP8 confocal microscope was used to analyse the samples. Ru 
compounds were excited at 488 nm and emission above 650nm was recorded. 
Time dependent localisation of complex 6 
HeLa cells were grown on the 12 mm Menzel–Gläser coverslips in 2 ml of complete medium 
at a density of 1.3 x 105 cells per ml. Cells were then treated with the complex 6 (14 µM) for 5 




media) for the last 25 min and with 100 nm Mitotracker Green FM for the last 15 min. HeLa 
cells were then fixed and images were taken on Leica SP8 confocal microscope.  
Indirect Immunofluorescence  
HeLa cells were grown on the 12 mm Menzel–Gläser coverslips in 2 ml of complete medium 
at a density of 1.3 x 105 cells per ml. Cells were then treated with the complex 6 (14 µM) for 
2h. Cells were co-stained with NucBlue (2 drops per 1 ml of media) for the last 25 min and 
with 100 nm Mitotracker Green FM for the last 15 min. HeLa cells were then fixed with 
paraformaldehyde solution in PBS (4%). Fixed cells were then incubated in blocking solution 
(0.2% BSA, 0,05 % Saponin in PBS) for 15 min at RT, and incubated with indicated primary 
antibodies for 1 h, anti-GM130 (BD Biosciences, catalog number 610823, batch 4324839) anti-
TGN46 (AbD Serotec, AHP500), anti-KDEL (Santa Cruz Biotechnology, catalog number sc-
58774) and anti-LAMP antibodies (BD Biosciences) were used at 1:1000, 1:1000. 1:50 and 
1:3000 dilution, respectively and detected using Alexa 488 conjugated secondary antibodies 
(Jackson ImmunoResearch Laboratory) at 1:400 dilution. Coverslips were mounted on glass 
slides using Prolong Glass Antifade Mountant. Leica SP8 confocal microscope was used to 
analyse the samples. Ru compounds were excited at 488 nm and emission above 650nm was 
recorded. Images were recorded in Cellular and Molecular Imaging Technical Platform, 
INSERM UMS 025 - CNRS UMS 3612, Faculty of Pharmacy of Paris, Paris Descartes 
University, Paris, France. Colocalisation values were calculated using Fiji software.26 
Seahorse mito stress test 
CT-26 cells were seeded in Seahorse XFe96 well plate at density of 30 000 cells per well in 80 
µl. After 24 h cells were treated with 1 µM concentration of: complex 6, cisplatin or 5-ALA 
according to the plate arrangement (Figure S53). After 4 h incubation media was exchanged for 
fresh complete media and chosen wells were irradiated for 2 h at 595 nm using a LUMOS-BIO 
photoreactor (Atlas Photonics). Each well was individually illuminated with a LED at constant 
current. Wells that were not irradiated were covered with aluminium foil. After irradiation 
regular media was removed and the cells were washed thrice using bicarbonate and serum free 
DMEM, supplemented with glucose, 1.8 mg/ mL; 1% glutamine and 1% sodium pyruvate and 
incubated in a non-CO2 incubator at 37 °C for 1 h. Mito Stress assay was run using Oligomycin, 
1 μM, FCCP 1 μM and mixture of Antimycin-A/ Rotenone 1 μM each in ports A, B and C 
respectively using Seahorse XFe96 Extracellular Flux Analyzer.  




CT-26 cells were seeded in Seahorse XFe96 well plate at density of 30 000 cells per well in 80 
µl. After 24 h cells were treated with 1 µM concentration of: complex 6, cisplatin or 5-ALA 
according to the plate arrangement (Figure S53). After 4 h incubation media was exchanged for 
fresh complete media and chosen wells were irradiated for 2 h at 595 nm using a LUMOS-BIO 
photoreactor (Atlas Photonics). Each well was individually illuminated with a LED at constant 
current. Wells that were not irradiated were covered with aluminium foil. After irradiation 
regular media was removed and the cells were washed thrice using bicarbonate and serum free 
DMEM and incubated in a non-CO2 incubator at 37 °C for 1 h. Glycolytic stress test was run 
using glucose, 10 mM, Oligomycin, 1 μM and 2-Deoxyglucose, 50 mM in ports A, B and C 
respectively using Seahorse XFe96 Extracellular Flux Analyzer. 
Generation of 3D HeLa MCTS 
HeLa cells were seeded at a density of 5000 cells per well in 200 µL in low attachment round 
bottom plates (Corning 4515). The single cells would generate MCTS approximately 400 µm 
in diameter at day 4 at. Plates were kept in the incubator at 37 °C with 5 % CO2. 
(Photo-)cytotoxicity in 3D HeLa MCTSs 
HeLa MCTSs after 4 days of growing at 37 °C and 5 % CO₂ were treated by replacing half of 
the medium in the well by the treatment solutions. For untreated reference MCTS, half of the 
medium was replaced by fresh medium only. For dark treatment, the cells were treated with 
increasing concentration of compounds for 24 h. Then medium was removed and replaced by 
fresh culture medium followed by 44 h incubation in the dark. For phototoxicity treatment, cells 
were also treated for 24 h with increasing concentration of compounds in the dark. Then 
medium was removed and replaced by fresh culture medium prior to 2 h of irradiation at 595 nm 
in using a LUMOS-BIO photoreactor (Atlas Photonics). Each well was individually illuminated 
with a LED at constant current. Plates were incubated for 44 h. The cytotoxicity was measured 
using CellTiter-Glo Cell viability kit (Promega, USA).  
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Table S1. Cartesian coordinates of the optimized structure of complex 1. 
X Y Z
C -0.55825800 -1.96095500 2.11992700
C -1.32520200 -2.95947100 2.73615900
C -2.57829600 -3.25637400 2.24465400
C -3.06351800 -2.54957200 1.12647700
C -4.34971300 -2.77696100 0.53919300
C -4.76366600 -2.06185400 -0.54228300
C -3.92623100 -1.06012200 -1.13032600
C -4.29645200 -0.29247000 -2.25201600
C -3.41537600 0.64568400 -2.74488300
C -2.17012700 0.81945000 -2.12553800
C -2.65677500 -0.81781200 -0.56873200
C -2.22376500 -1.56600500 0.56718600
C 2.17016700 0.81998000 2.12493100
C 3.41540600 0.64639700 2.74433400
C 4.29647000 -0.29192300 2.25176300
C 3.92622600 -1.05989200 1.13031100
C 4.76365600 -2.06180800 0.54257700
C 4.34968700 -2.77729400 -0.53863300
C 3.06349400 -2.55009700 -1.12600800
C 2.57828400 -3.25721700 -2.24396500
C 1.32523200 -2.96035700 -2.73563200
C 0.55834500 -1.96157600 -2.11979800
C 2.22376000 -1.56630200 -0.56706400
C 2.65675600 -0.81777000 0.56865400
Ru 0.00000600 0.22859500 -0.00022700
N -0.99051300 -1.27662700 1.06515800
N 0.99057200 -1.27692700 -1.06521200
N 1.79285000 0.10923100 1.06602700
N -1.79284000 0.10902500 -1.06640500
C -0.44617000 3.06821300 0.58482200
C -0.92736500 4.22724500 1.19106300
C -1.76280900 4.12552500 2.29500100
C -2.10011900 2.86312400 2.76981300
C -1.58958200 1.74883800 2.12081700
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N -0.78172800 1.84151000 1.05500000
C 0.44577800 3.06833800 -0.58496600
C 0.92665100 4.22749500 -1.19122600
C 1.76249300 4.12600500 -2.29488000
C 2.10055300 2.86368500 -2.76939100
C 1.59016100 1.74927200 -2.12050900
N 0.78185400 1.84172300 -1.05501100
H 0.42737700 -1.70452600 2.49214500
H -0.91820400 -3.48203200 3.59416400
H -3.19246400 -4.02400000 2.70531200
H -4.99091900 -3.53494500 0.97817000
H -5.74040200 -2.23999000 -0.98131900
H -5.26612700 -0.44670400 -2.71513600
H -3.66460500 1.25466200 -3.60622700
H -1.46034500 1.54863800 -2.49979900
H 1.46044700 1.54933800 2.49896400
H 3.66460000 1.25561600 3.60551800
H 5.26612700 -0.44607100 2.71494300
H 5.74039300 -2.23979800 0.98167400
H 4.99088400 -3.53545400 -0.97732300
H 3.19236900 -4.02509300 -2.70431500
H 0.91824800 -3.48322900 -3.59345700
H -0.42724300 -1.70521600 -2.49216800
H -0.65585400 5.20236000 0.80614600
H -2.14396300 5.02035900 2.77520200
H -2.74834400 2.73302700 3.62865400
H -1.82296300 0.74556400 2.45707300
H 0.65454100 5.20253300 -0.80652900
H 2.14336700 5.02094900 -2.77510000
H 2.74927400 2.73376100 -3.62788300
H 1.82399000 0.74603000 -2.45659800
C -0.55825800 -1.96095500 2.11992700
Table S2. Cartesian coordinates of the optimized structure of complex 2. 
X Y Z
C -0.07795000 -2.37011400 2.04174200
C 0.32568500 -3.60818400 2.56061300
C 1.31528700 -4.32403000 1.92216300
C 1.90355100 -3.79521800 0.75601800
C 2.94035400 -4.45376100 0.01953800
C 3.47380500 -3.89001300 -1.09806300
C 3.01386200 -2.62127900 -1.57764400
C 3.52375400 -1.98850100 -2.72878300
C 3.00941000 -0.76736500 -3.10807600
C 1.98774400 -0.17986700 -2.34937000
C 1.99103700 -1.95698000 -0.87205500
C 1.43499600 -2.54604600 0.30320100
C -1.56193800 -1.78469500 -2.04093000
C -2.70290000 -2.40839000 -2.56423700
C -3.91682100 -2.24903100 -1.93155800
C -3.98555500 -1.46251700 -0.76485100
C -5.19478500 -1.23175700 -0.03303300
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C -5.20065800 -0.46041000 1.08795300
C -3.99750700 0.14509900 1.57450900
C -3.93918300 0.94994600 2.72956400
C -2.72876200 1.48439400 3.11592000
C -1.57975800 1.21744900 2.35880200
C -2.79515500 -0.06740100 0.87056500
C -2.78949300 -0.87426400 -0.30749800
Ru -0.01503200 -0.03870600 0.00290600
N 0.45927900 -1.84594200 0.94408400
N -1.60435600 0.46121700 1.26472800
N -1.59689100 -1.03364400 -0.94402000
N 1.48548700 -0.75448500 -1.26026800
C 1.50067100 2.41741700 0.53655200
C 2.42028500 3.29933200 1.09947700
C 3.27228800 2.88204500 2.12019800
C 3.15761600 1.55297200 2.53982700
C 2.22400400 0.72332600 1.94523900
N 1.40569800 1.13594600 0.96483800
C 0.56645400 2.78686400 -0.53971200
C 0.50322100 4.05765000 -1.10667100
C -0.40890400 4.33856700 -2.12228500
C -1.24015300 3.29281500 -2.53468400
C -1.12999900 2.05013200 -1.93640200
N -0.24843700 1.78987300 -0.95969200
C 4.26992100 3.81019400 2.73863800
C -0.50591700 5.69915200 -2.73788000
H -0.85122800 -1.78695900 2.52882300
H -0.14985300 -3.98327900 3.45956300
H 1.64436800 -5.28488300 2.30535500
H 3.29602800 -5.41564000 0.37498400
H 4.26145600 -4.39513300 -1.64839000
H 4.31339100 -2.46417600 -3.30208700
H 3.37626100 -0.25032700 -3.98723400
H 1.56385700 0.77688800 -2.63169300
H -0.59683400 -1.89347200 -2.52363100
H -2.61095300 -3.00690200 -3.46313700
H -4.81443300 -2.72172300 -2.31872100
H -6.11179700 -1.68614300 -0.39435100
H -6.12213400 -0.29021100 1.63584300
H -4.84220000 1.13957100 3.30183200
H -2.64503500 2.10859500 3.99817600
H -0.61608700 1.62388300 2.64610800
H 2.47817800 4.32222900 0.74617300
H 3.79053000 1.15908600 3.32862200
H 2.11379600 -0.30878100 2.25742000
H 1.16634900 4.84067500 -0.75845900
H -1.97288800 3.43801600 -3.32151000
H -1.75819100 1.22235800 -2.24443200
H 0.30326600 6.35063800 -2.40323800
H -1.45787400 6.16877300 -2.46884600
H -0.47506000 5.63420600 -3.82934700
H 5.28477600 3.42546400 2.60120800
H 4.10038400 3.89662000 3.81620100
H 4.21682500 4.80776400 2.29847600
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Table S3. Cartesian coordinates of the optimized structure of complex 3. 
X Y Z
C -2.95990900 1.45739100 1.64568700
C -3.96399900 2.41394600 1.84886500
C -4.27762300 3.29701200 0.83843100
C -3.58135300 3.21976500 -0.38393100
C -3.82628000 4.08976800 -1.49461600
C -3.11898000 3.96750300 -2.65083900
C -2.10802500 2.96383600 -2.79611500
C -1.34710700 2.78479700 -3.96830200
C -0.39896700 1.78549600 -4.00844800
C -0.20846700 0.96578700 -2.88747000
C -1.84926300 2.09620200 -1.71632800
C -2.58966500 2.22597200 -0.50312100
C -0.20847700 -0.96578800 2.88747000
C -0.39898600 -1.78549300 4.00845000
C -1.34713200 -2.78478800 3.96830400
C -2.10804500 -2.96382700 2.79611400
C -3.11900500 -3.96749000 2.65083700
C -3.82630000 -4.08975500 1.49461100
C -3.58136500 -3.21975600 0.38392500
C -4.27763100 -3.29700200 -0.83844000
C -3.96400000 -2.41393900 -1.84887400
C -2.95990700 -1.45738700 -1.64569400
C -2.58967300 -2.22596700 0.50311600
C -1.84927500 -2.09619800 1.71632600
Ru -0.78219500 -0.00000100 -0.00000100
N -2.28539300 1.36210300 0.50369400
N -2.28539500 -1.36210000 -0.50369900
N -0.91194200 -1.11014100 1.76844800
N -0.91193500 1.11014100 -1.76845000
C 2.05739200 -0.66425700 -0.31634600
C 3.22242900 -1.36150000 -0.62729100
C 3.10534200 -2.60656500 -1.22357200
C 1.85510600 -3.13916700 -1.50235400
C 0.74457800 -2.38206700 -1.16110100
N 0.83186300 -1.17644100 -0.58315100
C 2.05739200 0.66425200 0.31634900
C 3.22243100 1.36149300 0.62729600
C 3.10534500 2.60655700 1.22357700
C 1.85511000 3.13916200 1.50235700
C 0.74458000 2.38206400 1.16110300
N 0.83186400 1.17643700 0.58315200
Br 4.69898900 -3.60306300 -1.66699600
Br 4.69899300 3.60305300 1.66700200
H -2.69178700 0.75514800 2.42677600
H -4.47823500 2.44364400 2.80248500
H -5.05054800 4.04741600 0.97246100
H -4.59117500 4.85348300 -1.39384900
H -3.31075100 4.63153800 -3.48778000
H -1.51426600 3.43141700 -4.82430800
H 0.20512100 1.61696300 -4.89245600
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H 0.52832200 0.17060800 -2.89958300
H 0.52831700 -0.17061500 2.89958300
H 0.20509900 -1.61696000 4.89246000
H -1.51429800 -3.43140400 4.82431100
H -3.31078200 -4.63152200 3.48777800
H -4.59119800 -4.85346700 1.39384200
H -5.05055800 -4.04740400 -0.97247100
H -4.47823300 -2.44363600 -2.80249600
H -2.69178100 -0.75514500 -2.42678200
H 4.19826000 -0.94813400 -0.40953300
H 1.73098500 -4.10889300 -1.96798100
H -0.25478900 -2.74960300 -1.36091800
H 4.19826100 0.94812500 0.40953900
H 1.73098900 4.10888700 1.96798400
H -0.25478700 2.74960100 1.36091800
Table S4. Cartesian coordinates of the optimized structure of complex 4. 
X Y Z
C 2.67238300 -1.29449200 1.77240700
C 3.66829400 -2.23527000 2.06874500
C 3.96207400 -3.22620600 1.15710600
C 3.25461300 -3.27192300 -0.06043200
C 3.47848000 -4.26014700 -1.07213300
C 2.75978600 -4.25701700 -2.22773600
C 1.75826000 -3.26312600 -2.47172600
C 0.98542300 -3.20576200 -3.64817800
C 0.04694400 -2.20654200 -3.78866500
C -0.12090700 -1.26552900 -2.76361800
C 1.52177500 -2.27912000 -1.49133000
C 2.27267400 -2.28462300 -0.27728700
C -0.09831600 1.26289600 2.76188100
C 0.08174400 2.20148300 3.78705500
C 1.02701200 3.19380800 3.64286000
C 1.79439000 3.24660400 2.46261400
C 2.80188200 4.23339100 2.21432100
C 3.51452400 4.23236700 1.05495600
C 3.27839600 3.24664400 0.04355400
C 3.97906700 3.19687600 -1.17779500
C 3.67322000 2.20887800 -2.08868200
C 2.67232300 1.27484900 -1.78777800
C 2.29053400 2.26623700 0.26470700
C 1.54571200 2.26534300 1.48250200
Ru 0.48295100 -0.00262700 -0.00261300
N 1.98660200 -1.31399600 0.63323400
N 1.99286200 1.29828900 -0.64487400
N 0.61210700 1.28694800 1.63801900
N 0.59490300 -1.29372200 -1.64326600
C -2.35513600 -0.61135500 0.39803600
C -3.51390200 -1.25720200 0.81200300
C -3.42732100 -2.41716800 1.57421600
C -2.16212100 -2.91588000 1.87827800
C -1.04478800 -2.22903400 1.42714000
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N -1.12879700 -1.09928700 0.71261600
C -2.35185800 0.62571100 -0.39537100
C -3.50706500 1.27388000 -0.81531900
C -3.41529400 2.44581300 -1.55858300
C -2.14721200 2.92593700 -1.88071000
C -1.03344800 2.22707100 -1.43906100
N -1.12299800 1.10595000 -0.71177000
C -4.72361200 -3.06995700 1.97700100
C -4.71105300 3.07928700 -1.99441100
O -5.74488200 2.42029100 -1.98950000
N -4.65058500 4.36503200 -2.38758800
N -4.66264300 -3.94037000 3.00203700
O -5.75595000 -2.80636500 1.37073300
H 2.42023900 -0.51063600 2.47757800
H 4.19113800 -2.16785700 3.01581700
H 4.72714300 -3.96796400 1.36497800
H 4.23685900 -5.01649400 -0.89601800
H 2.93534300 -5.01107300 -2.98861600
H 1.13555600 -3.94508700 -4.42887700
H -0.56657100 -2.13073900 -4.67895200
H -0.84990000 -0.46857000 -2.85466800
H -0.83323100 0.47155900 2.85513000
H -0.52780700 2.12941400 4.68037600
H 1.18659300 3.93115600 4.42354500
H 2.98688100 4.98543200 2.97496100
H 4.27741000 4.98338600 0.87558200
H 4.74838900 3.93324100 -1.38918600
H 4.19040700 2.13859600 -3.03864900
H 2.41075900 0.49340200 -2.49222400
H -4.49803000 -0.88490500 0.55412000
H -2.01707100 -3.83532300 2.43427100
H -0.04554600 -2.58749300 1.64258900
H -4.49326200 0.88884000 -0.58576200
H -1.99471400 3.81085700 -2.48811600
H -0.03262400 2.56485900 -1.67916900
H -3.84583700 4.94804300 -2.22977800
H -5.51422500 4.82025900 -2.64026600
H -3.86038700 -4.01650800 3.60482100
H -5.52569400 -4.35443100 3.31935200
Table S5. Cartesian coordinates of the optimized structure of complex 5. 
X Y Z
C -3.24699200 1.80178400 1.24947200
C -4.24267300 2.78782100 1.21960900
C -4.53541800 3.42499900 0.03277500
C -3.82645500 3.06811200 -1.13105500
C -4.04862600 3.66798200 -2.41248700
C -3.32946400 3.28315900 -3.50201300
C -2.32874800 2.26321600 -3.40466000
C -1.55470400 1.82115500 -4.49549700
C -0.61578700 0.83178800 -4.29552800
C -0.44949200 0.28160400 -3.01704400
21 
C -2.09372800 1.65730500 -2.15420100
C -2.84497400 2.06375900 -1.01031100
C -0.44301300 -0.28189200 3.01493200
C -0.60500700 -0.83257000 4.29376000
C -1.54001300 -1.82527300 4.49550100
C -2.31449400 -2.27015600 3.40611800
C -3.31149400 -3.29354900 3.50541200
C -4.03142600 -3.68085600 2.41727400
C -3.81380200 -3.08021300 1.13542100
C -4.52393900 -3.43937100 -0.02698900
C -4.23590100 -2.80097900 -1.21432200
C -3.24367300 -1.81152300 -1.24611800
C -2.83595500 -2.07255500 1.01276100
C -2.08389500 -1.66353300 2.15518800
Ru -1.05561300 -0.00134200 -0.00048200
N -2.55980300 1.44484200 0.16817800
N -2.55535500 -1.45250200 -0.16622800
N -1.16230900 -0.67871100 1.96894200
N -1.16833700 0.67573600 -1.96972000
C 1.79365900 0.72187200 0.16529700
C 2.94540100 1.47369000 0.32610100
C 2.89541500 2.84836400 0.64295000
C 1.59440700 3.38505000 0.78178600
C 0.48992200 2.58134100 0.60853400
N 0.56001800 1.27196800 0.30856300
C 1.79565500 -0.71571200 -0.16923800
C 2.94949600 -1.46395200 -0.33200000
C 2.90317800 -2.83767600 -0.65298800
C 1.60388200 -3.37738700 -0.79490400
C 0.49707200 -2.57781400 -0.61698400
N 0.56361000 -1.26928200 -0.31266500
C 4.11786700 3.58173300 0.79619500
C 4.12782100 -3.56767200 -0.80681400
C 4.19511500 -4.90710700 -1.08585200
C 4.18139400 4.91952200 1.08517600
N 5.29938000 5.64415400 1.23380300
N 5.31438900 -5.62400500 -1.26468600
C 6.59996200 5.02459500 1.09381100
C 5.25299800 7.05779100 1.54452200
C 6.61427800 -4.99759900 -1.15425400
C 5.27215200 -7.06025100 -1.44583000
H -2.99514900 1.29154900 2.17263000
H -4.76720900 3.03522600 2.13546000
H -5.30070900 4.19362200 -0.01523000
H -4.80585600 4.44146200 -2.49644500
H -3.50348200 3.74479900 -4.46904300
H -1.70389800 2.26127600 -5.47673300
H -0.00055000 0.46713000 -5.11015100
H 0.27996300 -0.49941800 -2.83367100
H 0.28329900 0.50171200 2.83012400
H 0.01039800 -0.46563900 5.10723600
H -1.68585300 -2.26586200 5.47703200
H -3.48210700 -3.75570900 4.47280200
H -4.78586600 -4.45689500 2.50269700
22 
H -5.28648200 -4.21062500 0.02249400
H -4.76155000 -3.05000800 -2.12909300
H -2.99558500 -1.30018900 -2.16968800
H 3.91506000 1.00471400 0.20329400
H 1.42998900 4.42855700 1.02499000
H -0.50920700 2.98958900 0.71461600
H 3.91785500 -0.99253600 -0.20831800
H 1.44274800 -4.41959100 -1.04573600
H -0.50095100 -2.98840500 -0.72442000
H 5.03627700 3.01776600 0.66626700
H 5.04450300 -3.00020900 -0.68016000
H 3.28291600 -5.48966600 -1.18517500
H 3.26757100 5.49342300 1.21440600
H 6.72066100 4.58994900 0.09468100
H 6.73790800 4.22980800 1.83632700
H 7.37426900 5.77733600 1.24155000
H 4.21507800 7.38632900 1.61457400
H 5.75146100 7.64283800 0.76384900
H 5.74831600 7.26201000 2.50024400
H 6.68385100 -4.13472000 -1.82524100
H 7.38405000 -5.71700300 -1.43414100
H 6.80782000 -4.65737900 -0.12933300
H 4.23674400 -7.38956200 -1.54452700
H 5.72206400 -7.57804400 -0.59060500
H 5.81749800 -7.34797200 -2.35069400
Table S6. Cartesian coordinates of the optimized structure of complex 6. 
X Y Z
C -0.20433800 -1.17647900 -2.17035000
C -0.83768700 -2.19745200 -2.88108300
C -2.14772700 -2.55525600 -2.59848900
C -2.82562400 -1.81031300 -1.59155300
C -4.19804200 -2.00280500 -1.23596800
C -4.79827800 -1.25281400 -0.27122500
C -4.08926500 -0.22937900 0.43408000
C -4.65964700 0.58031500 1.45798800
C -3.81925800 1.47587300 2.10313400
C -2.48188000 1.60417000 1.72416000
C -2.73076100 -0.02705700 0.11118900
C -2.10614700 -0.79978900 -0.91914000
C 0.20420800 -1.17670100 2.17037000
C 0.83744300 -2.19788000 2.88091700
C 2.14742600 -2.55578700 2.59822600
C 2.82542100 -1.81071000 1.59146500
C 4.19786000 -2.00320000 1.23596500
C 4.79817800 -1.25310300 0.27135900
C 4.08924000 -0.22958300 -0.43389700
C 4.65971100 0.58018700 -1.45770400
C 3.81938900 1.47588300 -2.10275500
C 2.48200600 1.60420900 -1.72382100
C 2.73073400 -0.02721900 -0.11103600
23 
C 2.10604300 -0.80002500 0.91919100
Ru 0.00002000 1.00417700 0.00010800
N -0.80906000 -0.49579700 -1.20172100
N 1.94328200 0.88646700 -0.74342000
N 0.80898600 -0.49594900 1.20182400
N -1.94323900 0.88651600 0.74365000
C -0.33309400 3.84788000 -0.65614600
C -0.68410800 5.00726100 -1.34357000
C -1.31312700 4.93440100 -2.58495800
C -1.57105400 3.65697700 -3.09169300
C -1.19826500 2.54107100 -2.36375700
N -0.58835100 2.62180000 -1.17170100
C 0.33344400 3.84783200 0.65638400
C 0.68459900 5.00717700 1.34381800
C 1.31361300 4.93424500 2.58518800
C 1.57126200 3.65678000 3.09199900
C 1.19835500 2.54092900 2.36405900
N 0.58852700 2.62173200 1.17194900
C -1.68879800 6.16523500 -3.34905400
C 1.69010700 6.16500400 3.34900100
H 0.82491600 -0.90956800 -2.38243200
H -0.27621300 -2.73201400 -3.63936400
H -4.77001500 -2.76145400 -1.75723800
H -5.83680100 -1.43482700 -0.02066000
H -4.20273600 2.11552600 2.89031800
H -1.83054900 2.31694400 2.21726100
H -0.82500400 -0.90968800 2.38252700
H 0.27592800 -2.73250800 3.63912200
H 4.76979900 -2.76187300 1.75724200
H 5.83673600 -1.43503800 0.02088900
H 4.20292400 2.11562800 -2.88983600
H 1.83073700 2.31707900 -2.21686700
H -0.46971000 5.97917200 -0.91455900
H -2.06111100 3.52524800 -4.05076300
H -1.38408100 1.54090100 -2.73760400
H 0.47025800 5.97911100 0.91483800
H 2.06115900 3.52499700 4.05114500
H 1.38394300 1.54073100 2.73794600
H 1.52118100 7.06976000 2.76214100
H 2.74308900 6.13076400 3.64399700
H 1.09967500 6.23704100 4.26849500
H -2.73948600 6.12794100 -3.65161400
H -1.09201100 6.24102500 -4.26417200
H -1.52692200 7.06950000 -2.75945000
C 6.08425900 0.50396200 -1.84614200
C 6.43095000 0.38449700 -3.19851800
C 7.10336800 0.60773200 -0.88913300
C 7.76736900 0.35301000 -3.58310200
H 5.64807500 0.29762100 -3.94683800
C 8.43872000 0.58488500 -1.27870900
H 6.84922300 0.73662600 0.15901700
C 8.77400100 0.45296200 -2.62473100
H 8.02230200 0.24873600 -4.63344600
H 9.21836100 0.67673600 -0.52853600
24 
H 9.81699300 0.43141300 -2.92625900
C 2.77721700 -3.67179100 3.33586400
C 3.38981300 -4.73553600 2.65898400
C 2.71668100 -3.70072900 4.73534200
C 3.93544100 -5.79983500 3.36982000
H 3.41301300 -4.74291600 1.57305200
C 3.27176800 -4.76207200 5.44273700
H 2.24914500 -2.87774100 5.26868200
C 3.88231400 -5.81358300 4.76216000
H 4.39779300 -6.62279700 2.83314500
H 3.22827600 -4.76644100 6.52771700
H 4.31273600 -6.64317000 5.31506300
C -6.08420300 0.50413400 1.84642500
C -6.43087800 0.38386300 3.19872800
C -7.10330200 0.60874200 0.88949800
C -7.76729800 0.35236500 3.58332200
H -5.64799300 0.29638000 3.94696900
C -8.43864900 0.58587700 1.27909400
H -6.84916700 0.73837800 -0.15856700
C -8.77392800 0.45311400 2.62503600
H -8.02222000 0.24746100 4.63360600
H -9.21829100 0.67838100 0.52900200
H -9.81691900 0.43155200 2.92656400
C -2.77763800 -3.67097600 -3.33643600
C -3.39106200 -4.73445800 -2.65989200
C -2.71642300 -3.69993100 -4.73589000
C -3.93677300 -5.79852600 -3.37100300
H -3.41492300 -4.74173200 -1.57397900
C -3.27159100 -4.76103600 -5.44357200
H -2.24831100 -2.87712300 -5.26900200
C -3.88291800 -5.81230200 -4.76331500
H -4.39977400 -6.62127900 -2.83456600
H -3.22755900 -4.76540700 -6.52853000
H -4.31340400 -6.64170500 -5.31644300
Table S7. Cartesian coordinates of the optimized structure of complex 7. 
X Y Z
C -0.79242200 -1.98975200 2.04237000
C -1.63210200 -2.95676000 2.59828300
C -2.85947500 -3.25014500 2.02177900
C -3.19790600 -2.56234100 0.82163200
C -4.38992100 -2.80175100 0.06712700
C -4.66066800 -2.11624900 -1.07750800
C -3.76177600 -1.12927000 -1.59259700
C -3.99399800 -0.37741000 -2.77968800
C -3.06059800 0.59470400 -3.10917100
C -1.91778100 0.78499800 -2.32985300
C -2.58111200 -0.86950600 -0.86502200
C -2.28962900 -1.60032900 0.33120000
C 1.91754400 0.78562200 2.33002000
C 3.06047200 0.59580100 3.10929700
C 3.99438100 -0.37575500 2.77961800
25 
C 3.76258900 -1.12747700 1.59235600
C 4.66205200 -2.11381600 1.07703400
C 4.39165200 -2.79926200 -0.06771800
C 3.19944600 -2.56042800 -0.82210500
C 2.86133100 -3.24826200 -2.02232000
C 1.63374700 -2.95552300 -2.59869300
C 0.79357000 -1.98903500 -2.04261900
C 2.29065000 -1.59900400 -0.33148500
C 2.58176600 -0.86823300 0.86486000
Ru 0.00001000 0.18367700 0.00004700
N -1.11021300 -1.30780100 0.94633800
N 1.11104600 -1.30703300 -0.94652500
N 1.66347500 0.06386700 1.24287400
N -1.66333100 0.06318800 -1.24282900
C -0.50282300 3.03536600 0.54115400
C -1.03199700 4.18908700 1.09504000
C -1.99022800 4.14247900 2.12992600
C -2.35380400 2.84322900 2.55332700
C -1.79108200 1.73656300 1.95762000
N -0.88080700 1.80312200 0.96933800
C 0.50120300 3.03578200 -0.54044500
C 1.02969600 4.18992800 -1.09409800
C 1.98791700 4.14408700 -2.12903100
C 2.35226500 2.84513700 -2.55269200
C 1.79021700 1.73802000 -1.95719100
N 0.87991100 1.80385200 -0.96888900
C -2.51350000 5.36676100 2.66300600
C 2.51041300 5.36878800 -2.66190700
C 3.47075600 5.43497300 -3.63604400
C -3.47430400 5.43215400 3.63673700
N -3.96865800 6.54940200 4.19123700
N 3.96433600 6.55265300 -4.19035100
C -3.50880600 7.85166500 3.75949900
C -5.09301700 6.50314400 5.10299600
C 3.50407500 7.85454600 -3.75792700
C 5.08799800 6.50725400 -5.10300800
H 0.15541500 -1.74390700 2.50822100
H -1.32501900 -3.45291400 3.51248100
H -5.08824600 -3.55234300 0.41843300
H -5.58083600 -2.31436200 -1.61465400
H -3.19057100 1.19671900 -4.00185700
H -1.17432900 1.52577900 -2.60235600
H 1.17368100 1.52594000 2.60266400
H 3.19012700 1.19770200 4.00210700
H 5.58238800 -2.31144700 1.61407100
H 5.09040700 -3.54937900 -0.41918700
H 1.32686900 -3.45175700 -3.51291800
H -0.15441600 -1.74365700 -2.50841600
H -0.71067800 5.15748300 0.72881600
H -3.07279300 2.68270800 3.34863100
H -2.06667800 0.73848200 2.28028900
H 0.70780700 5.15807200 -0.72770200
H 3.07133800 2.68521600 -3.34803700
H 2.06640500 0.74015600 -2.28002100
26 
H -2.11439000 6.28401000 2.24140600
H 2.11097900 6.28570400 -2.23988700
H 3.90462000 4.52198900 -4.03586600
H -3.90792400 4.51882600 4.03603200
H -3.83249600 8.07292800 2.73452800
H -2.41587800 7.90276500 3.79724900
H -3.91405200 8.61364300 4.42591600
H -5.29800100 5.46888400 5.38360600
H -5.99458000 6.92380600 4.64158400
H -4.87042900 7.07350500 6.01037700
H 2.41111200 7.90521300 -3.79528200
H 3.90878200 8.61696900 -4.42416000
H 3.82802600 8.07551200 -2.73297800
H 5.29340300 5.47317400 -5.38397200
H 5.98965600 6.92839300 -4.64222400
H 4.86435200 7.07763800 -6.01011900
C -5.16755400 -0.59254900 -3.65354800
C -5.94945300 0.50099700 -4.04841300
C -5.48500900 -1.86723700 -4.14295300
C -7.03403500 0.32100800 -4.90073500
H -5.71464200 1.49175100 -3.66939900
C -6.56531800 -2.04196700 -5.00212000
H -4.86739100 -2.71896900 -3.87270000
C -7.34487600 -0.95026300 -5.37913100
H -7.63828000 1.17567000 -5.18993600
H -6.79401700 -3.03315700 -5.38207200
H -8.19016300 -1.08947600 -6.04645600
C -3.74978200 -4.24363100 2.65963600
C -5.08562900 -3.93836700 2.95538300
C -3.24165000 -5.49649700 3.02714100
C -5.89485000 -4.87092900 3.59661000
H -5.48299400 -2.95817700 2.70800900
C -4.05618100 -6.42944100 3.66065500
H -2.20903700 -5.74381800 2.79701400
C -5.38436800 -6.11937500 3.94629500
H -6.92511600 -4.61817800 3.82859000
H -3.65253300 -7.40096600 3.92966400
H -6.01895300 -6.84729000 4.44292100
C 3.75222000 -4.24110600 -2.66037200
C 3.24500300 -5.49441700 -3.02759900
C 5.08772300 -3.93476500 -2.95655800
C 4.06011400 -6.42675600 -3.66126300
H 2.21266100 -5.74255700 -2.79714100
C 5.89751500 -4.86672300 -3.59794300
H 5.48435300 -2.95422000 -2.70940500
C 5.38795900 -6.11562700 -3.94733900
H 3.65718300 -7.39864000 -3.93005100
H 6.92750200 -4.61314500 -3.83026400
H 6.02299100 -6.84307000 -4.44408300
C 5.16800300 -0.59055100 3.65347500
C 5.48587000 -1.86518800 4.14275100
C 5.94951900 0.50321700 4.04846700
C 6.56621900 -2.03964000 5.00192400
H 4.86852700 -2.71709700 3.87241900
27 
C 7.03414400 0.32350400 4.90079600
H 5.71437200 1.49392800 3.66954900
C 7.34540200 -0.94771200 5.37906400
H 6.79524300 -3.03079100 5.38178200
H 7.63809300 1.17834000 5.19010200
H 8.19072100 -1.08671100 6.04639400
Scheme S1. Synthesis of the desired complexes 1-7. a) EtOH/H2O (1:1), 18 h reflux under N2 
atmosphere. b) EtOH/H2O (1:1), 18 h reflux under N2 atmosphere. c) tert-Butoxy 
bis(dimethylamino)methane, 140 °C, 16 h under N2 atmosphere. 
28 
Figure S1. 1H NMR spectrum of 1 in CD3CN, 500 MHz. 
Figure S2. 13C NMR spectrum of 1 in CD3CN, 125 MHz. 
29 
Figure S3. 1H NMR spectrum of 2 in CD3CN, 400 MHz. 
Figure S4. 13C NMR spectrum of 2 in CD3CN, 100 MHz. 
30 
Figure S5. 1H NMR spectrum of 3 in CD3CN, 500 MHz. 
Figure S6. 13C NMR spectrum of 3 in CD3CN, 125 MHz. 
31 
Figure S7. 1H NMR spectrum of 4 in CD3CN, 400 MHz. 
Figure S8. 13C NMR spectrum of 4 in CD3CN, 100 MHz. 
32 
Figure S9. 1H NMR spectrum of 5 in CD3CN, 400 MHz. 
Figure S10. 13C NMR spectrum of 5 in CD3CN, 125 MHz. 
33 
Figure S11. 1H NMR spectrum of 6 in CD3CN, 400 MHz. 
Figure S12. 13C NMR spectrum of 6 in CD3CN, 125 MHz. 
34 
Figure S13. 1H NMR spectrum of 7 in CD3CN, 500 MHz. 
Figure S14. 1H NMR spectrum of 7 in CD3CN, 125 MHz. 
35 
Figure S15. The molecular structure of 1 with displacement ellipsoids drawn at the 20% 
probability level. Solvent molecules, counterions and hydrogen atoms are excluded for clarity. 
Figure S16. The molecular structure of 2 with displacement ellipsoids drawn at the 20% 
probability level. Solvent molecules, counterions and hydrogen atoms are excluded for clarity. 
36 
Figure S17. The molecular structure of 3 with displacement ellipsoids drawn at the 20% 
probability level. Solvent molecules, counterions and hydrogen atoms are excluded for clarity. 
37 
Table S8. Crystal data and structure refinement parameters for 1 and 2. 
1 2
CCDC number   1969709 1969708 
Empirical formula  C38H30F12N8P2Ru  C41H38.5F12N6O1.25P2Ru  
Formula weight  989.71  1026.29  
Temperature/K  183(1)  183(1)  
Crystal system  monoclinic  triclinic  
Space group  P21/c  P-1
a/Å  12.4678(3)  12.8029(3)
b/Å  27.4167(4)  13.1575(2)
c/Å  13.2004(3)  16.2010(4)
α/°  90  79.9877(16)
β/°  118.159(3)  75.692(2)
γ/°  90  62.241(2)
Volume/Å3  3978.16(16)  2334.63(10)
Z  4  2
ρcalcg/cm3  1.652  1.460
μ/mm-1  4.832  4.143
F(000)  1984.0  1037.0
Crystal size/mm3  0.11 × 0.06 × 0.04  0.39 × 0.15 × 0.03
Radiation  CuKα (λ = 1.54184) CuKα (λ = 1.54184)
2Θ range for data collection/° 6.448 to 148.99 7.6 to 149.0
Index ranges  -15 ≤ h ≤ 14, -30 ≤ k ≤ 34, -16 ≤ l ≤ 16  -15 ≤ h ≤ 15, -16 ≤ k ≤ 15, -20 ≤ l ≤ 20
Reflections collected  30861  44520  
Independent reflections  8116 [Rint = 0.0339, Rsigma = 0.0251]  9539 [Rint = 0.0221, Rsigma = 0.0130]  
Data/restraints/parameters  8116/114/524  9539/86/627  
Goodness-of-fit on F2  1.150  1.089  
Final R indexes [I>=2σ (I)] R1 = 0.0756, wR2 = 0.1785 R1 = 0.0491, wR2 = 0.1495 
Final R indexes [all data] R1 = 0.0782, wR2 = 0.1799 R1 = 0.0523, wR2 = 0.1562 
Largest diff. peak/hole / e Å-3 1.13/-0.79  1.36/-0.35  
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Table S9. Crystal data and structure refinement parameters for 3. 
3 
CCDC number 1969710 
Empirical formula  C38H28Br2F12N8P2Ru  
Formula weight  1147.51  
Temperature/K  183(1)  
Crystal system  triclinic  












Crystal size/mm3  0.29 × 0.25 × 0.17
Radiation  MoKα (λ = 0.71073)
2Θ range for data collection/°  4.42 to 55.75
Index ranges  -15 ≤ h ≤ 15, -16 ≤ k ≤ 16, -19 ≤ l ≤ 19
Reflections collected  38483
Independent reflections  9850 [Rint = 0.0490, Rsigma = 0.0378]
Data/restraints/parameters  9850/312/643
Goodness-of-fit on F2  1.031
Final R indexes [I>=2σ (I)]  R1 = 0.0398, wR2 = 0.1020
Final R indexes [all data]  R1 = 0.0488, wR2 = 0.1096
Largest diff. peak/hole / e Å-3  0.79/-0.61
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Figure S18. Difference density plots calculated between ES and GS (top row) computed for 
the first vertical transition and the first bright state MLCT transition of 6 (a) and 7 (b). For 7 
both transitions are of MLCT type while the first one of 6 (a) is an inter-ligand charge transfer 
π-π* transition. Yellow regions are characterized by an increase in density upon excitation 
while blue ones show a decrease in electron density. The barycenters are depicted as spheres 
(bottom rows) and the corresponding distances of charge transfer RDCT (in Å) are stated above. 
Atoms color scheme: C - green; H - white; N - blue; O - red, Ru - brown. 
Table S10. Spectroscopic properties of complexes 1-7 in CH3CN at room temperature. 
RDCT  = 1.063RDCT  = 1.382
Compound 6 




UV/Vis Absorption  









200 (73.2), 225 (64.3), 264 (86.5),  
284 (44.1), 446 (15.0) 
600 0.027 130 766 
2 
202 (77.9), 222 (61.5), 264 (81.7),  
280 (43.9), 421 (12.8), 449 (13.9) 
606 0.050 110 918 
3 
201 (72.9), 223 (91.0), 263 (95.2), 289 
(45.1), 388 (11.5), 441 (14.8) 
645 0.014 207 617 
4 
201 (100.1), 223 (91.3), 263 (105.8),  
308 (28.2), 386 (13.8), 438 (16.7), 441 
(16.8) 
654 0.020 326 1387 
5 
201 (89.3), 224 (81.2), 265 (91.1), 379 






192 (183.4), 279 (126.3), 441 (23.2),  
457 (23.2) 
623 0.021 161 1096 
7 







Figure S19. Measured UV/Vis spectra of the complexes 1-7 in CH3CN. 
Figure S20. Normalised emission spectra of the complexes 1-7 in CH3CN. 
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Figure S21. Lifetime spectra of the complexes 1 in aerated (above) and degassed (below) 
CH3CN. 
43 
Figure S22. Lifetime spectra of the complexes 2 in aerated (above) and degassed (below) 
CH3CN. 
44 
Figure S23. Lifetime spectra of the complexes 3 in aerated (above) and degassed (below) 
CH3CN. 
45 
Figure S24. Lifetime spectra of the complexes 4 in aerated (above) and degassed (below) 
CH3CN. 
46 
Figure S25. Lifetime spectra of the complexes 5 in aerated (above) and degassed (below) 
CH3CN. 
47 
Figure S26. Lifetime spectra of the complexes 6 in aerated (above) and degassed (below) 
CH3CN. 
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Table S11. Singlet oxygen quantum yields (Φ(1O2)) in CH3CN and aqueous solution 
determined by direct and indirect methods by excitation at 450 nm. Average of three 









1 0.57 0.54 0.27 0.36
2 0.69 0.53 0.31 0.34
3 0.55 0.56 n.d. 0.21
4 0.62 0.59 0.25 0.26
5 0.24 0.30 n.d. 0.21
6 0.61 0.63 n.d. 0.05
7 0.22 0.35 n.d. 0.07
n.d. = not determinable, Φ(1O2) <0.20.
Figure S28. 1H NMR spectrum of 1 in DMSO-d6 after preparation (green) and 7 days (red). 
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Figure S29. 1H NMR spectrum of 2 in DMSO-d6 after preparation (green) and 7 days (red). 
Figure S30. 1H NMR spectrum of 3 in DMSO-d6 after preparation (green) and 7 days (red). 
51 
Figure S31. 1H NMR spectrum of 4 in DMSO-d6 after preparation (green) and 7 days (red). 
52 
Figure S32. 1H NMR spectrum of 5 in DMSO-d6 after preparation (green), 1 day (olive), 2 
days (blue) and 7 days (red). 
53 
Figure S33. 1H NMR spectrum of 6 in DMSO-d6 after preparation (green) and 7 days (red). 
54 
Figure S34. 1H NMR spectrum of 7 in DMSO-d6 after preparation (green), 1 day (olive), 2 days 




Figure S35. HPLC chromatogram (Method M1) of Caffeine (internal standard) and 1 after 48 h 
incubation in human pooled plasma. 
Caffeine 
48 h 
Figure S36. HPLC chromatogram (Method M1) of Caffeine (internal standard) and 2 after 
48 h incubation in human pooled plasma. 
Caffeine 
48 h 
Figure S37. HPLC chromatogram (Method M1) of Caffeine (internal standard) and 3 after 48 h 




Figure S38. HPLC chromatogram (Method M1) of Caffeine (internal standard) and 4 after 48 h 







Figure S39. HPLC chromatogram (Method M2) of Caffeine (internal standard) and 5 after 0 h, 




Figure S40. HPLC chromatogram (Method M1) of Caffeine (internal standard) and 6 after 48 h 







Figure S41. HPLC chromatogram (Method M2) of Caffeine (internal standard) and 7 after 
0 h, 4 h, 12 h, 24 h and 48 h incubation in human pooled plasma.  
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Figure S42. Temporal change of the UV/Vis spectra of [Ru(bipy)3]Cl2 by irradiation at 
450 nm in CH3CN. 
Figure S43. Temporal change of the UV/Vis spectra of complex 1 by irradiation at 450 nm in 
CH3CN. 
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Figure S44. Temporal change of the UV/Vis spectra of complex 2 by irradiation at 450 nm in 
CH3CN.  
Figure S45. Temporal change of the UV/Vis spectra of complex 3 by irradiation at 450 nm in 
CH3CN. 
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Figure S46. Temporal change of the UV/Vis spectra of complex 4 by irradiation at 450 nm in 
CH3CN. 
Figure S47. Temporal change of the UV/Vis spectra of complex 5 by irradiation at 450 nm in 
CH3CN.  
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Figure S48. Temporal change of the UV/Vis spectra of complex 6 by irradiation at 450 nm in 
CH3CN.  
Figure S49. Temporal change of the UV/Vis spectra of complex 7 by irradiation at 450 nm in 
CH3CN. 
62 
Figure S50. Temporal change of the UV/Vis spectra of Protoporphyrin IX by irradiation at 
450 nm in CH3CN. 
Table S12. Distribution coefficients of 1-7 between an organic octanol and aqueous phosphate 
buffer saline phase.  
Compound logP 
1 +0.2 ± 0.2
2 +0.3 ± 0.2
3 +0.4 ± 0.3
4 +0.2 ± 0.2
5 +0.7 ± 0.3
6 +1.4 ± 0.3
7 +1.7 ± 0.2
63 
Figure S51. Comparison of the cellular uptake of complexes 1–7 after 4 h incubation in HeLa 
cells. 
Figure 52. Time-dependent accumulation of complex 6 (14 µM) in HeLa cell line. DNA 
visualised by NucBlue staining, mitochondria visualised using Mitotracker Green FM 
(100 nm), complex 6 shown in red. Scale bar, 20 µm. 
64 
Figure S53. Plate arrangement for Seahorse Mito Stress and Glycolysis Stress experiments. 
Figure S54. Oxygen consumption rates and different respiration parameters in CT-26 cells 
alone or after treatment with various test compounds. 
65 
Figure S55. Extracellular acidification rates and different glycolysis parameters in CT-26 cells 
alone or after treatment with various test compounds. 
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